Preventing rapid platelet accumulation under very high shear stress by Para, Andrea N.
PREVENTING RAPID PLATELET ACCUMULATION







of the Requirements for the Degree
Doctor of Philosophy in the
Woodruff School of Mechanical Engineering
Georgia Institute of Technology
August 2012
PREVENTING RAPID PLATELET ACCUMULATION
UNDER VERY HIGH SHEAR STRESS
Approved by:
Dr. David Ku, Advisor
Woodruff School of Mechanical
Engineering
Georgia Institute of Technology
Dr Todd Sulchek
Woodruff School of Mechanical
Engineering





Wallace H. Coulter Department of
Biomedical Engineering




Date Approved: May 2, 2012
To my family and friends,
and the many friends who have become family.
iii
ACKNOWLEDGEMENTS
I would like to begin by thanking my advisor, Dr Ku, for your guidance and encour-
agement over the last seven years. You have taught me the importance of constantly
challenging myself and always pursuing my goals. Thank you for this incredible ex-
perience.
I would also like to thank my committee: Dr Deckmyn, Dr Meeks, Dr Sulchek
and Dr Barabino as well as Dr Roberts, who funded this project. Your conversations,
both personal and professional have been incredibly helpful. It is an honor to have
gotten to work with you all.
I would also like to thank everyone in the Phlebotomy Lab at Georgia Tech (Jack
Horner, LaShonna Stokes, Lisa Carr, Kenneth Butts and Richard Hoose) - you all
have made this last seven years such a wonderful journey! The morning would not be
the same without your wit, stories, and advice. Thanks for keeping me in line. You
are all very special to me. Ken - All of the researchers and donors send you our very
best wishes for a speedy recovery.
To my friends from the KULAK - Karen Vanhoorelbeke, Karen De Ceunynck,
Bauke De Maeyer, Katleen Broos (and Benjamin and Casper), Hendrik Feys (and
Jennifer and Nina) and Isabelle Salles - Thank you all for opening your homes to me
and taking me through your cities. You all have created incredibly fond memories
and Belgium would not have been the same without your kindness.
I have gotten to know a lot of people throughout this process, many of which
have become family. To Mamtaben - thanks for being such an awesome sister and
running buddy and for always reminding me how much flatter TX is than GA. Pooja
- you already know from your real sister that you are an amazing person, so positive
iv
and encouraging, but please know you have another fan. Rahul - I have missed our
football games and gratuitous food binges, but consider myself very lucky for all of
our conversations and visits. Srin - my other Indian bhaiya - you are probably one
of the funniest, most outspoken people I know and I would be remiss in saying that
I am a little surprised that the Secret Service allowed you into the Whitehouse. We
are all so lucky that Pooja is a lawyer. To my other Indian family - Pritty, Murali,
Kartik B, Smitha, Tanvi, Yash, Ayona, Avika, Popo and Kartik S - you guys have
provided so much levity and fun to this experience, I can’t thank you enough not to
mention the food! I can’t wait until our next reunion.
Further, I need to thank my wingmates who put up with my antics. Julia H -
you are not only an incredible researcher, you are an amazing woman, confidant and
Polish sister. Our ”Finer Things” club was a sight to behold. To Rachel W - your
amazing brunches, clothing outings and dinners were the setting dreams are made
out of. It could only be topped by your amazing capacity for kindness and patient
ear. I don’t know how I did not meet you earlier, but I am so glad I finally found
you! To Roxanne - you are an amazing and talented woman. I can’t wait to be a
customer at your bakery and get to see your amazing cakes in magazines! Katie M -
I have thoroughly enjoyed our wildly productive coffee sessions. You are a woman I
admire and I am very lucky to have gotten to know you better. Kelly S - We know
each-other far too well to ever not be friends. You have been a great personal advisor,
workout buddy and pub crawl coordinator - always providing a good laugh or helpful
advice. To Tamera - you are completely my other half and I am so glad we got to
work in the lab for 2 years together. You are an amazing person; it almost makes up
for the fact that JP is always wrong. JP - you are hilarious and have been so fun to
get to know over the years but, I am sorry, Tamera is funnier. Andrew S - I want
to thank you for always providing levity and putting up with my practical jokes. I
could always count on you for a coffee break and an interesting conversation. Thanks
v
for introducing me to the other half of ”Team Andrea”. Chris H - you and Ally have
been a blast to hang out with during this experience. I will miss our endless rides on
the Emory bus, trading off the crossword, and having awesome Superbowl Sundays
at your house.
To the Glezer lab - thank you guys for helping me feel like an honorary member,
for the great talks and many meals we have shared. Your terrible taste in movies is
easily made up for by being one of the most genuine groups of men I have ever met.
Thank you for being so kind.
My current labmates: Marmar, Daniel, Mark and Susan - thank you for putting
up with me. You have all been incredibly encouraging during this process. I will miss
our random conversations and long walks. Thank you so much for your support. You
have made this lab an easy place to come to every day.
A special thank you is reserved for my family, which has come to include not
only my parents and brother, but now includes Teresa, Christopher, Joshua, and my
”outlaws”, Maud and David. You all have been so supportive during this process -
your words of encouragement have gotten me through some very rough times and I
cannot be thankful enough for having you in my life. Thanks for being brave enough
to answer the phone. Please know I love you all.
Lastly, to Abe. I can’t believe how lucky I was to have met you on the first day
of grad school. You are an amazing man, my best friend, an incredible researcher




DEDICATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . iii
ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . iv
LIST OF TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix
LIST OF FIGURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . x
SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xvi
I INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.0.1 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
II RAPID PLATELET ACCUMULATION LEADING TO THROM-
BOTIC OCCLUSION . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
2.0.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
2.0.3 Experimental Design and Methods . . . . . . . . . . . . . . . 13
2.0.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.0.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.0.6 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.0.7 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
III A LOW-VOLUME, SINGLE PASS IN-VITRO SYSTEM TO STUDY
HIGH SHEAR THROMBOSIS WITH HUMAN BLOOD . . . . 38
3.0.8 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
3.0.9 Experimental Design and Methods . . . . . . . . . . . . . . . 41
3.0.10 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
3.0.11 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
3.0.12 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.0.13 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
IV PREVENTING RAPID PLATELET ACCUMULATION IN WHOLE,
HUMAN BLOOD UNDER HIGH SHEAR STRESS BY BLOCK-
ING αIIBβ3 AND PLATELET ACTIVATION . . . . . . . . . . . . 60
4.0.14 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
vii
4.0.15 Experimental Design and Methods . . . . . . . . . . . . . . . 62
4.0.16 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
4.0.17 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
4.0.18 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
4.0.19 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
V THROMBOSIS IS INCREASED BY EXCESS AMOUNTS OF VON
WILLEBRAND FACTOR AT VERY HIGH SHEAR RATES . . 96
5.0.20 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
5.0.21 Experimental Design and Methods . . . . . . . . . . . . . . . 97
5.0.22 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
5.0.23 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
5.0.24 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
5.0.25 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
VI DISCUSSION OF THESIS RESULTS AND FUTURE STUDIES 117
6.0.26 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
APPENDIX A — CH3 SUPPLEMENTARY FIGURES . . . . . . 122
viii
LIST OF TABLES
1 The percentage of final thrombus volume included in each definition of
initial deposition and RPA as well as their respective rates of growth. It
can be seen that initial deposition is faster than RPA when measured
as first visible thrombus vs. last 50% of final thrombus volume (a,
n = 6, p<0.05) as well as first 7.6 min vs. last 7.6 min (b, n = 6,
p<0.05). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2 Initial visible formation occurred significantly faster in the porcine
gravitationally fed model than either the porcine syringe pump model
(γ,p<0.05) or the human syringe pump model (β, p<0.05). The porcine
syringe pump model formed initial visible formation significantly faster
than the human syringe pump model (α, p<0.05). . . . . . . . . . . . 52
3 The ability of each investigatory drug to inhibit RPA is shown above
for two subjects. A (+) indicates RPA prevention. Otherwise, (– ) is
shown. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
4 The maximum volumes are shown in this table for all experiments and
saline controls. The p values for the vWF enhanced blood just missed
statistical significance. . . . . . . . . . . . . . . . . . . . . . . . . . . 110
5 The RPA rates for all of the vWF experiments and their controls are
shown above. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
ix
LIST OF FIGURES
1 (a) Schematic diagram of the in vitro hemodynamic system. Whole
blood flow originates on a raised platform to provide a constant grav-
ity head of 30 mmHg and flows through a stenotic tube to an open
outlet. A pressure transducer is used to monitor the upstream pres-
sure and a graduated cylinder and stopwatch are used to measure flow
rate. A high resolution digital camera records thrombus formation
in the test section through a low power binocular microscope. (b)
Image of an 82% stenosis. The gradual geometry is characteristic of
all stenoses used in these experiments. (c) Measurement of thrombus
volume. Measurements of the thrombus lumen diameter are taken ap-
proximately every 0.17 mm of the outer diameter created by the lumen
of the tube and the inner diameter created by thrombus growth into
the tube. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2 Series of photographs demonstrating the growth of thrombus under
high shear stress in varying percent stenoses. Flow is from left to
right. (a) A 70% stenosis by diameter is shown at 4.8, 9.3, and 15.8
min from the onset of flow. (b) A 75% stenosis by diameter is shown
at 5.4, 8.0 and 14.4 min. (c) An 83% stenosis by diameter is shown at
3.82, 7.9, and 9.8 min. . . . . . . . . . . . . . . . . . . . . . . . . . . 18
3 (a) Flow from left to right: Carstairs staining enables the composition
of the thrombus to be observed. Platelets: gray-blue to navy; fibrin:
deep red; red blood cells: yellow; collagen: bright blue. (b) Micro-
computed tomography of the lumen of a 75% stenosis following partial
thrombus growth into the lumen. The image shown is the shape of the
lumen after thrombus has protruded into the flow. . . . . . . . . . . . 20
4 Two controls were utilized for this experiment: (a) collagen coated
non-stenotic tubes. (b) Stenotic tube without collagen coating. It
can be seen that no significant deposition forms on either the collagen
coated or the stenosis without collagen. Deposition can be seen as
areas stained with analine blue. As the tube is filled with PBS, some
light reflections can be seen in the image. . . . . . . . . . . . . . . . . 21
5 (a) This graph shows the fraction of the total diameter filled with
thrombus at occlusion in relation to the apex of the stenosis. (b) This
graph illustrates where the mean deposition of all of the stenotic test
sections (n = 6) occurs with respect to the apex diameter at occlusion,
with the average of all of the local stenosis diameters represented by
the gray squares. Taking the mean of all of the inner diameters creates
a representative stenosis that is 81% stenosed by diameter. . . . . . . 23
x
6 (a) Volume growth of thrombus over time until occlusion for six test
sections. (b) Thrombus growth over time for an 80% stenosis. The
initial rate of platelet deposition can be seen to have a visibly smaller
slope (black dashed line) than the final rate of the half of formation
leading to occlusion (RPA, gray dotted line). . . . . . . . . . . . . . . 24
7 Initial deposition and rapid platelet accumulation formation rates in
cm3 ∗10−6min−1, n = 6. RPA (20±4.5∗10−6cm3min−1) is significantly
faster than initial deposition (3.1 ± 1.7 ∗ 10−6cm3min−1, p <0.05). . . 25
8 Regression lines describe a change in the rate of thrombus growth dur-
ing initial deposition and rapid platelet accumulation. The intersection
between the two lines occurred at approximately 7.6 min. . . . . . . . 26
9 (A) Gravitationally fed experiments required an initial 240mLs of blood
to be placed on a platform 30cm above the stenosis. During experimen-
tation, blood flowed from the raised platform, past a pressure trans-
ducer, through the collagen coated test section and onto a scale where
mass flow measurements were taken in real time. (B) The syringe
pump experiment required a maximum of 30mLs of blood for experi-
mentation to occlusion. Blood flowed, driven by a syringe pump, from
a syringe, past a pressure transducer and through the collagen coated
test section. Both systems are single pass. . . . . . . . . . . . . . . . 42
10 Thrombus formation using human blood in an 86% stenosis. Initial
visible formation in this stenosis is seen as very slight formation which
occurred in 5.4 minutes (A) and is highlighted by the green box. Fol-
lowing initial formation, subsequent platelet deposition occurs (B) until
complete occlusion (C). . . . . . . . . . . . . . . . . . . . . . . . . . . 45
11 Human thrombus stained using Carstairs staining highlights platelets
in navy blue. It can be seen from this stain that an occlusive thrombus
formed from human blood is predominantly platelets. . . . . . . . . . 46
12 Human blood deposits in the stenosis in two phases -initial visible
formation followed by a faster Rapid Platelet Accumulation. . . . . . 47
13 Thrombus deposits significantly slower during visible initial deposition
(p<0.05) than RPA. The mean is denoted with a black circular dot
and outliers are marked with an ∗. . . . . . . . . . . . . . . . . . . . . 48
14 Thrombus deposits significantly slower during visible initial deposition
(p<0.05) than RPA. . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
15 Porcine blood forms similarly in both the syringe pump (A) and the
gravitationally fed (B) models. Following visible initial adhesion, more
diffuse deposition (I) and, ultimately, occlusion occur (II). . . . . . . 50
xi
16 Thrombus formation in both the gravitationally fed (A) and syringe
pump models (B) are dominated by platelets (navy) in porcine blood.
Platelets are stained using Carstairs Staining protocol and flow during
formation was from left to right. The scale for both samples is indicated
above. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
17 Rapid Platelet Accumulation Rates in the human syringe pump model
are significantly lower (p<0.05, n=21) than either the porcine gravita-
tionally fed model (n=6) or the porcine syringe pump model (n=7). . 53
18 Whole blood is perfused from a syringe pump, past a pressure trans-
ducer and through a pyrex, collagen coated test section which is placed
under a microscope. A high resolution camera takes images in real time
through the microscope. . . . . . . . . . . . . . . . . . . . . . . . . . 62
19 Experiments were completed in a three step approach. Initially, up
to 10mLs of untreated blood was perfused through a collagen coated
test section until visible initial thrombus deposition occurred (A). This
was followed by perfusing up to 10mLs of blood treated with an anti-
thrombotic agent through the same test section (B). Lastly up to
10mLs of untreated blood was perfused through the test section (C).
Times shown are relative to the initiation of flow for that particular step. 64
20 (A) Adherent embolus is debris which enters the test section quickly
(A1,A2), but remains for minutes during experimentation (A3). In
the event shown, the embolus shifted near the end of experimentation
(A4). (B) Transient embolus also occurs during experimentation and is
seen as rapidly transiting debris (B1-B4), which exits the tube within
seconds. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
21 Measured thicknesses following the perfusion of blood treated with
A) PGE1 and the subsequent perfusion of B)untreated blood. There
was a significant increase in maximum thicknesses (∗, p<0.05) for
D)untreated blood following the perfusion of treated blood when com-
pared to C)blood treated with PGE1. The averages with standard
deviations for E)treated blood and F)untreated blood are also shown. 70
22 Calculated volumes are shown for blood treated with PGE1 (A) and
subsequently perfused untreated blood (B) . . . . . . . . . . . . . . . 71
23 Measured thicknesses following the perfusion of blood treated with A)
2-MeSAMPS (n=5) and the subsequent perfusion of B)untreated blood
(n=4). There was a significant increase in the maximum thicknesses
(∗, p<0.05) for D)untreated blood (n=4) following the perfusion of
treated blood when compared to C)blood treated with 2-MeSAMPS
(n=5). The averages with standard deviations for E)treated blood and
F)untreated blood are also shown. . . . . . . . . . . . . . . . . . . . . 73
xii
24 Calculated volumes are shown for blood treated with 2-MeSAMPS (A)
and subsequently perfused untreated blood (B). Volumes are lower for
treated blood. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
25 The average measured A)thickness and calculated B)volume of blood
which was treated with 2-MeSAMPS (n=4). . . . . . . . . . . . . . . 76
26 Measured thicknesses following the perfusion of blood treated with A)
ASA (n=7) and the subsequent perfusion of B)untreated blood (n=3).
There was a significant increase in maximum thickness(∗, p<0.05) for
D)untreated blood following the perfusion of ASA treated blood (n=3)
and C)blood treated with ASA (n=7). The averages with standard
deviations for E)treated blood and F)untreated blood are also shown. 78
27 Calculated volumes are shown for blood treated with ASA (A) and
subsequently perfused untreated blood (B). . . . . . . . . . . . . . . . 79
28 Measured thicknesses following the perfusion of blood treated with
A) abciximab and the subsequent perfusion of B) untreated blood.
There was a significant increase in thickness (∗, p<0.05) in the average
maximal thickness for D)untreated blood following the perfusion of
treated blood when compared to C) blood treated with abciximab.
The averages with standard deviations for E) treated blood and F)
untreated blood are also shown. . . . . . . . . . . . . . . . . . . . . . 81
29 Volume deposition over time was calculated for blood treated with
abciximab (A) and untreated blood which was subsequently perfused
(B). The average added volume deposited in the untreated blood (32
± 22 ∗10−6cm3, n=6) was significantly greater than the average max-
imal added volume in the blood treated with abciximab (1.4 ± 7.0
∗10−6cm3, n=6, p<0.05). . . . . . . . . . . . . . . . . . . . . . . . . . 82
30 Measured thicknesses following the perfusion of blood treated with A)
eptifibatide and the subsequent perfusion of B)untreated blood. The
average maximal thickness was also represented for blood treated with
eptifibatide (n=5, C) and untreated blood perfused following (n=4,
D). The averages with standard deviations for E)treated blood and
F)untreated blood are also shown. . . . . . . . . . . . . . . . . . . . . 84
31 The average measured A)thickness and calculated B)volume of blood
which was treated with eptifibatide in which RPA was prevented (n=4). 85
32 The added maximal thrombus volume deposited was calculated for
both blood treated with eptifibatide (A) and untreated blood (B). . . 86
xiii
33 Whole blood is perfused from a syringe pump, past a pressure trans-
ducer and through a pyrex, collagen coated test section which is placed
under a microscope. A high resolution camera takes images in real time
through the microscope. . . . . . . . . . . . . . . . . . . . . . . . . . 97
34 Thicknesses for each sample were measured in the stenosis for vWF
enriched blood (A). Average thicknesses was also calculated for vWF
enriched blood samples (B). Thickness was also measured for control
blood in which saline was added (C). Average thickness for the control
was also calculated (D). All started at an initial shear rate of 3,500s−1. 102
35 Thicknesses for each sample were measured in the stenosis with a vWF
enriched surface (A). Average thicknesses were calculated for vWF
enriched surface samples (B). Thickness was also measured for the
control in which saline was added to the surface (C). The average for
the control is also shown (D). All flow experiments started at an initial
shear rate of 3,500s−1. . . . . . . . . . . . . . . . . . . . . . . . . . . 103
36 Thrombosis thickness formed at high shear rates (3,500s−1), with vWF
enriched Blood (above) and vWF enriched surfaces (Below) There is
a significantly greater average thickness in vWF enriched blood (n=6)
versus a vWF enriched surfaces (n=3, p<0.05). . . . . . . . . . . . . 104
37 Volume growth of thrombus over time at 3,500s−1 for individual ex-
periments. (A) Blood enriched with vWF, (B) saline enriched blood,
(C) Surface enriched with vWF, (D) and the saline surface controls. . 105
38 Thrombus thicknesses for vWF enriched blood at an initial shear rate
of 10,000s−1. (A) Individual thickness. (B) Average thickness. (C)
Thickness for control blood in which saline was added. (D) Average
thickness for saline control. The average thickness with vWF enriched
blood (n=5) was greater than the saline control (n=3, p<0.05). . . . 106
39 Thrombosis thicknesses at a shear rate of 10,000s−1: (A) vWF enriched
surface. (B) Average thickness for the treated samples . (C) Thickness
for the control in which saline was added to the surface. (D) Average
thickness for the control. . . . . . . . . . . . . . . . . . . . . . . . . . 107
40 Thrombus average thickness at very high shear rates (10,000s−1) from
vWF enriched blood (above) and vWF enriched surface (below). There
was no significant difference in average thickness on a surface coated
with vWF versus the control surface coated with saline (p=0.525). . . 108
41 Volume over time is shown for vWF enriched blood (A), saline enriched
blood (B), vWF enriched surface (C) and the saline enriched surface
(D) at 10,000s−1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
xiv
42 The RPA rates for all vWF experiments are shown above as compared
with previous experiments with untreated blood at 3,500s−1 (n=21).
illustrating the wide range of accumulation rates seen in individuals.
Note that the entire range of accumulation rates is much greater than
the initial deposition rates that average 0.8 ± 1.0 µm3 µm−2 min−1
(n=21) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
43 A detailed image of the syringe pump components are shown above.
Flow is from left to right. Blood flows from the syringe pump, past the
pressure transducer and into the stenotic test section. During exper-
imentation there is usually a tube connected to the downstream end
of the stenosis so that the blood cleanly flows into a waste container
(not shown). The 3-way valve used posessed a 1.6mm inner diameter
ensuring that the highest shear was located in the throat of the stenosis.122
44 Scatter plot of time versus volume of blood required for visible initial
formation in the human syringe pump model, the porcine syringe pump
model and the porcine gravitationally fed model. . . . . . . . . . . . . 123
45 The average time to visible initial formation is shown above for the
human syringe pump model, the porcine syringe pump model and the
porcine gravitationally fed model. The bars denote the standard de-
viation. The time to initial formation for the human syringe pump
model is significantly higer (7.4 ± 3.8 min) than the porcine syringe
pump model (2.7 ± 4.9 min, α, p<0.05) and the porcine gravitation-
ally fed model (1.0 ± 0.9min, β, p<0.05). The porcine gravitationally
fed model is significantly faster (γ, p<0.05) then the porcine syringe
pump model. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
xv
SUMMARY
Atherosclerosis is a major cause of mortality in industrialized nations. Atheroscle-
rosis is characterized by plaque deposition which decreases the lumen diameter into a
stenosis. The creation of a restriction increases shear rates pathologic levels exceeding
3,500s−1. Following plaque cap rupture, thrombus may form from the accumulation of
millions of platelets, occluding the vessel, leading to heart attack and stroke. Studies
of high shear thrombosis show that platelet activation, αIIbβ3 and vWF are involved.
However, some recent studies also suggest that high shear aggregation is not depen-
dent on activation or αIIbβ3. Several antiplatelet pharmaceuticals against activation
and αIIbβ3 have been proposed, but their efficacy in patients remain mixed. The over-
all objective of this project is to determine the factors necessary for thrombosis to
occlusion in very high shear regions seen in diseased arteries. Our central hypotheses
are that platelet activation and the subsequent conformational change in αIIbβ3 are
necessary for thrombosis, and that higher concentrations of vWF in the plasma will
increase thrombosis.
To this end, we developed a new high shear hemodynamic model utilizing 30mLs
of whole blood and quantified thrombus thickness, volume accumulation and accu-
mulation rates. We demonstrate that thrombosis to occlusion stems from a second
phase of Rapid Platelet Accumulation (RPA). Thrombus accumulation is completely
prevented by PGE1 inhibition of platelet activation. Similarly, αIIbβ3 blockade via
abciximab prevented significant thrombus deposition and RPA. We also found that
increasing plasma vWF levels in high shear regions increased thrombus thickness and
suggestively increased RPA rates. The results clarify the need for activation of mural






Cardiovascular disease is a major cause of mortality in industrialized nations.[9, 13, 25]
Atherosclerosis is a form of cardiovascular disease, characterized by plaque deposi-
tion which decreases the elasticity of the arteries and potentially decreases the lumen
diameter. A decrease in the lumen diameter can have a significant impact on the
shear rate, with normal vasculature attaining shear rates <1,500s−1, while patho-
logic, diseased arteries with restricted diameters are capable of shear rates exceeding
100,000s−1.[1, 20] Following either endothelial damage or the rupture of the plaque,
platelets deposit on the thrombogenic surface exposed. Platelet deposition can form a
platelet-rich plug which occludes the vessel, precipitating myocardial infarction (MI)
and stroke.[6, 28] The process of platelet accumulation, which may lead to occlusion,
is mediated by many factors, including: high shear, platelet activation, Glycoprotein
IIb/IIIa (αIIbβ3) and von Willebrand Factor (vWF).
Platelets in flow arrest onto a thrombogenic surface under arterial conditions via
Glycoprotein Ib (GPIb) to vWF interactions.[2] Following initial adhesion, platelet ac-
tivation ensues, aiding platelet-platelet accumulation. Platelet activation is an event
which can lead to the release of platelet contents, shape change of the platelet and
the conformational change of αIIbβ3.[24] Aside from being stimulated by mechanical
forces via pathologic shear, activation can occur through pathways mediated by ADP
and Ca2+.[28]
The conformational change in αIIbβ3, one of the most abundant receptors on the
platelet surface with over 40,000 copies present, allows the protein to bind other pro-
teins such as vWF.[4, 7] vWF aids platelet-platelet attachment and is found in platelet
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alpha granules and the plasma of whole blood.[15] vWF is a shear dependent pro-
tein, elongating at shear rates exceeding 6,000s−1.[23] Elongation exposes the many
binding domains of vWF, allowing it to bind more readily than in its non-elongated
globular form.[19, 26] vWF’s A1, A3 and C1 domains, which bind GPIb, collagen and
αIIbβ3 respectively, allow vWF to participate in thrombosis.[21, 22, 29] After activa-
tion, the expulsion of the alpha granule from the platelet creates vWF concentrations
which are 50x higher on the surface of thrombotic growth than in whole blood.[10]
These proteins mediate thrombosis is differing ways - aiding platelet adhesion and
aggregation. Platelet adhesion refers to the arrest of a platelet onto a surface from
flow and, under the conditions of arterial thrombosis which include high shear stress
and collagen exposure, is usually mediated via GPIb.[2, 8] Aggregation refers to the
formation of a platelet-platelet mass (<100 platelets), sometimes due to shear prior
to adhesion.[20]
Recent studies by Flannery and Para with porcine blood suggest that the process
of thrombus formation occurs in two phases: an initial adherence of platelets onto a
surface followed by a faster type of platelet accumulation, Rapid Platelet Accumula-
tion (RPA).[12, 17] RPA is accumulation rates ≥ 1.6 µm3 µm−2 min−1.[17]
Studies conducted at lower shear rates (<3,000s−1) indicate proteins have shear
dependent behaviours, with proteins such as fibrinogen dominating platelet to platelet
aggregation at shear rates <2,600s−1, but not above.[27] Under very high shear con-
ditions (20,000s−1), Ruggeri et al showed that platelet aggregation was activation
independent, with both Ruggeri and Turitto further supporting the potential for a
different protein mechanism contributing to platelet accumulation under very high
shear stress.[20]
As αIIbβ3 is seen as the main receptor for adhesion and aggregation in the for-
mation of a platelet plug and platelet activation is necessary for the conformational
change required for αIIbβ3 to participate in high shear occlusion, it is important to
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determine the effect that blocking them will have on RPA.[4, 5] Further, as vWF aids
platelet to platelet deposition under high shear conditions it is important to deter-
mine if thrombosis can be increased by increasing vWF concentrations in the plasma
and at the surface of thrombotic formation.[15, 18] Therefore, to study thrombosis
in vitro, it is necessary to recreate the hemodynamic conditions that trigger arterial
thrombosis.
Previous studies have utilized parallel plate chambers, stenosis models and the
PFA-100 R© to study platelet deposition.[11, 12, 16, 17]
The parallel plate model is the most widely utilized model, often using fluores-
cence microscopy to measure the amount of deposited, fluoresced platelets on the
surface of the chamber.[16] While parallel plates can create very high shear con-
ditions, most utilize a recirculating blood arrangement that often activates all the
circulating platelets.[14] Further, parallel plate chambers utilize abrupt geometries
and a wide aspect ratio which may induce secondary flows not present in stenotic
arteries. However, the biggest drawback of the parallel plate system is that thrombus
growth in the depth direction is poorly resolved. The parallel plate chamber gives
an en face view of platelet deposition. Thus, the common parallel plate endpoint is
surface coverage of platelet attachment to an immobilized protein that may miss a
different phenomenon of platelet-platelet attachment. While intravascular thrombo-
sis requires the accumulations of hundreds of millions of platelets, this phenomenon
is poorly measured in parallel plate chambers. The study of such large volumes of
thrombosis requires high resolution thickness measurements in a range from 10 to
thousands of microns.
Tubular glass stenosis models, such as the gravitationally model created by Flan-
nery, et al, allow for the measurement of millions of platelet depositions accumulating
to occlusion, although require 240mLs of blood.[12, 17] This large blood volume re-
quirement is not a viable option for repeatable testing with human blood.
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The PFA-100 R© uses small amounts of blood to occlude a small filter at high shear
rates.[11] While the PFA-100 R© uses small amounts of blood under pathologic shear
conditions, it does not measure the thickness of thrombus formation deposited which
is necessary for the calculation of accumulation rates. Rather, it measures time to
occlusion of the filter which may include an embolic event due to upstream platelet
aggregation and not RPA. Further, the small aperture occludes within 5 minutes, a
time scale that likely represents only Phase I of attachment by thousands of platelets
instead of Phase II where millions of platelets accumulate to cause arterial thrombosis.
Therefore, we have created a syringe pump-fed stenosis model which allows for the
measurement of thrombus thickness . The thickness vs time data can be converted
into volume and accumulation rates. We utilize an in-vitro setup which exposes small
volumes (<30mLs) of whole, human blood to high shear conditions (>3,500s−1),
creating an environment which promotes large scale thrombosis.[3]
It is the goal of this dissertation to utilize an in-vitro hemodynamic model to
answer the following questions regarding the clinically-fatal, massive accumulation of
platelets under high shear conditions associated with an atherosclerotic stenosis:
• Are platelet-to-platelet thrombosis rates different than platelet-surface attach-
ment rates?
• Can we demonstrate stenotic thrombosis with less than 50 mls of whole blood
with a high resolution measurement of volume?
• Does human shear induced platelet thrombosis differ from porcine thrombosis?
• What are the rates of shear induced platelet accumulation in human blood?
• Is shear induced thrombus from human blood composed of mainly platelets?
• Does blocking αIIbβ3 prevent thrombosis under high shear stress conditions?
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• Does blocking αIIbβ3 prevent significant thrombus thickness deposition under
high shear stress conditions?
• Does blocking αIIbβ3 prevent significant thrombus volume deposition under very
high shear stress conditions?
• Does blocking activation prevent large-scale thrombosis under high shear stress
conditions?
• Does blocking activation prevent large-scale thrombus thickness deposition un-
der high shear stress conditions?
• Does blocking activation prevent large-scale thrombus volume deposition under
very high shear stress conditions?
• Does adding a high concentration of vWF to whole blood increase thrombosis
under high shear conditions?
• Does adding vWF to whole blood significantly increase thrombus thickness un-
der high shear conditions?
• Does adding a high concentration of vWF to a surface with initial deposition
increase thrombosis under high shear conditions?
• Does adding vWF to a surface with initial deposition significantly increase




[1] Bark, David Ku, D., “Wall shear over high degree stenoses pertinent to
atherothrombosis,” Journal of Biomechanics, vol. 43, pp. 2970–2977, 2010.
[2] Cauwenberghs, N., Meiring, M., Vauterin, S., van Wyk, V., Lam-
precht, S., Roodt, J. P., Novak, L., Harsfalvi, J., Deckmyn, H., and
Kotze, H. F., “Antithrombotic effect of platelet glycoprotein Ib - blocking
monoclonal antibody fab fragments in nonhuman primates,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 20, pp. 1347–1353, 2000.
[3] Chow, T. W., Hellums, J. D., Moake, J. L., and Kroll, M. H., “Shear
stress-induced von willebrand factor binding to platelet glycoprotein Ib initiates
calcium influx associated with aggregation,” Blood, vol. 80, no. 1, pp. 113–120,
1992.
[4] Coller, B., “Blockade of platelet gpIIb/IIIa receptors as an antithrombotic
strategy,” Circulation, vol. 92, pp. 2373–2380, 1995.
[5] Dav, G. and Patrono, C., “Platelet activation and atherothrombosis,” New
England Journal of Medicine, vol. 357, pp. 2482–2494, 2007.
[6] Davies, M. J. and Thomas, A. C., Plaque fissuring-the cause of acute myocar-
dial infarction, sudden ischaemic death, and crescendo angina, vol. 53. London,
ROYAUME-UNI: BMJ Publishing Group, 1985.
[7] de Walle, G. R. V., Schoolmeester, A., Iserbyt, B. F., Cosemans,
J. M. E. M., Heemskerk, J. W. M., Hoylaerts, M. F., Nurden, A.,
Vanhoorelbeke, K., and Deckmyn, H., “Activation of αIIbβ3 is a sufficient
6
but also an imperative prerequisite for activation of αIIbβ1 on platelets,” Blood,
vol. 109, pp. 595–602, 2007.
[8] Doggett, T. A., Girdhar, G., Lawshe, A., Schmidtke, D. W., Lau-
renzi, I. J., Diamond, S. L., and Diacovo, T. G., “Selectin-like kinetics
and biomechanics promote rapid platelet adhesion in flow: The gpIb α-vwf tether
bond,” Biophysical Journal, vol. 83, pp. 194–205, 2002.
[9] Eikelboom, J. W., Lonn, E., Jr., J. G., Hankey, G., and Yusuf, S., “Ho-
mocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic
evidence,” Annals of Internal Medicine, vol. 131, pp. 363–375, 1999.
[10] Harrison, P. and Cramer, E., “Platelet alpha-granules,” Blood Review,
vol. 7, pp. 52–62, 1993.
[11] Kratzer, M. and Born, G., “Simulation of primary haemostasis in vitro.,”
Haemostasis, vol. 15, pp. 357–62, 1985.
[12] Ku, D. N. and Flannery, C. J., “Development of a flow-through system to
create occluding thrombus,” Biorheology, vol. 44, no. 4, pp. 273–284, 2007.
[13] Larson, M. G., Atwood, L. D., Benjamin, E. J., Cupples, L. A., Sr,
R. B. D., Fox, C. S., Govindaraju, D. R., Guo, C.-Y., Heard-Costa,
N. L., Hwang, S.-J., Murabito, J. M., Newton-Cheh, C., O’Donnell,
C. J., Seshadri, S., Vasan, R. S., Wang, T. J., Wolf, P. A., and Levy,
D., “Framingham heart study 100k project: genome-wide associations for car-
diovascular disease outcomes,” BMC Medical Genetics, vol. 8, p. S5, 2007.
[14] Meiring, M. S., Litthauerb, D., Harsfalvic, J., van Wyka, V., Baden-
horsta, P. N., and d, H. F. K., “In vitro effect of a thrombin inhibition
peptide selected by phage display technology,” Thrombosis Research, vol. 107,
pp. 365 – 371, 2002.
7
[15] Moake, J. L., Tumer, N. A., Stathopoulos, N. A., Nolasco, L. H.,
and Hellums, J. D., “Involvement of large plasma von willebrand factor (vwf)
multimers and unusually large vwf forms derived from endothelial cells in shear
stress-induced platelet aggregation,” Journal of Clinical Investigation, vol. 78,
pp. 1456–1461, 1986.
[16] Muggli, R., Baumgartner, H., Tschopp, T., and Keller, H., “Auto-
mated microdensitometry and protein assays as a measure for platelet adhesion
and aggregation on collagen-coated slides under controlled flow conditions.,” The
Journal of Laboratory and Clinical Medicine, vol. 95, pp. 195–207, 1980.
[17] Para, A., Bark, D., Lin, A., and Ku, D., “Rapid platelet accumulation
leading to thrombotic occlusion,” Annals Of Biomedical Engineering, vol. 39,
pp. 1961–1971, 2011.
[18] Peterson, D. M., Stathopoulos, N. A., Giorgio, T. D., Hellums,
J. D., and Moake, J. L., “Shear-induced platelet aggregation requires von
willebrand factor and platelet membrane glycoproteins Ib and IIb-IIIa,” Blood,
vol. 69, no. 2, pp. 625–628, 1987.
[19] Ruggeri, Z. M., “The role of von willebrand factor in thrombus formation,”
Thrombosis Research, vol. 120, pp. S5 – S9, 2007.
[20] Ruggeri, Z. M., Orje, J. N., Habermann, R., Federici, A. B., and
Reininger, A. J., “Activation-independent platelet adhesion and aggregation
under elevated shear stress,” Blood, vol. 108, no. 6, pp. 1903–1910, 2006.
[21] Sadler, J. E., “Biochemistry and genetics of von willebrand factor,” Annual
Review of Biochemistry, vol. 67, no. 1, p. 395, 1998.
8
[22] Savage, B., Saldivar, E., and Ruggeri, Z. M., “Initiation of platelet adhe-
sion by arrest onto fibrinogen or translocation on von willebrand factor,” Cell,
vol. 84, pp. 289 – 297, 1996.
[23] Schneider, S. W., Nuschele, S., Wixforth, A., Gorzelanny, C.,
Alexander-Katz, A., Netz, R. R., and Schneider, M. F., “Shear-induced
unfolding triggers adhesion of von willebrand factor fibers,” Proceedings of the
National Academy of Sciences, vol. 104, no. 19, pp. 7899–7903, 2007.
[24] Shattil, S. J., Hoxie, J. A., Cunningham, M., and Brass, L. F., “Changes
in the platelet membrane glycoprotein IIb/IIIa complex during platelet activa-
tion,” Journal of Bioligical Chemistry, vol. 260, no. 20, pp. 11107–11114, 1985.
[25] Shiffman, D., Mikita, T., Tai, J. T. N., Wade, D. P., Porter, J. G.,
Seilhamer, J. J., Somogyi, R., Liang, S., and Lawn, R. M., “Large scale
gene expression analysis of cholesterol-loaded macrophages,” the Journal of Bi-
ological Chemistry, vol. 275, pp. 37324 – 37332, 2000.
[26] Siedlecki, C. A., Lestini, B. J., Kottke-Marchant, K., Eppell, S. J.,
Wilson, D. L., and Marchant, R. E., “Shear-dependent changes in the
three-dimensional structure of human von willebrand factor,” Blood, vol. 88,
pp. 2939–2950, 1996.
[27] Weiss, H. J., Hawiger, J., Ruggeri, Z. M., Turtto, V. T., Thiagara-
jan, P., and Hoffmann, T., “Fibrinogen-independent platelet adhesion and
thrombus formation on subendothelium mediated by glycoprotein lIb-Illa com-
plex at high shear rate,” Journal of Clinical Investigation, vol. 83, pp. 288–297,
1989.
9
[28] Wootton, D. M. and Ku, D. N., “Fluid mechanics of vascular systems,
diseases, and thrombosis,” Annual Review Of Biomedical Engineering, vol. 1,
pp. 299–329, 1999.
[29] Wu, D., Vanhoorelbeke, K., Cauwenberghs, N., Meiring, M., De-
praetere, H., Kotze, H. F., and Deckmyn, H., “Inhibition of the von
willebrand (vwf)-collagen interaction by an antihuman vwf monoclonal antibody
results in abolition of in vivo arterial platelet thrombus formation in baboons,”
Blood, vol. 99, pp. 3623–3628, 2002.
10
CHAPTER II
RAPID PLATELET ACCUMULATION LEADING TO
THROMBOTIC OCCLUSION
2.0.2 Introduction
An occluding, platelet-rich thrombus can cause sudden cardiac ischemic death in
under an hour.[11] The sequence of events in acute arterial thrombosis is poorly un-
derstood as the clinical event is rapid and difficult to observe. Many investigators have
utilized parallel plate chambers to study the formation of platelet deposition under
shear.[1, 24] In parallel plate systems, investigators typically study lower, physiologic
wall shear rates (<3500 s−1) with experimentation times of <5 min.[1, 19] Platelet
deposition under shear is thought to occur from Glycoprotein Ib (GPIb) on circulating
platelets adhering to collagen via fibrinogen or von Willebrand Factor (vWF).[8, 10]
Following the initial adhesion to the damaged vascular endothelium, Glycoprotein
IIb/IIIa (αIIbβ3), mediated by fibrinogen and vWF, enables attached platelets to
bind more firmly to other platelets following activation.[13, 22]
Alevriadou et al. measured a maximum deposition of approximately 20 ∗ 106
platelets cm−2 (0.5 µm3 µm−2 min−1) in a parallel plate flow chamber using 2 min
experimentation times and low, physiologic shear (1500 s−1).[1] Badimon et al. mea-
sured higher deposition rates at an increased shear (3380 s−1) to achieve a deposition
rate of 8 µm3 µm−2 min−1, while utilizing experimental times of 5 min.[3] Further
increasing shear, Barstad et al. reported deposition rates of 12 µm3 µm−2 min−1
utilizing high pathologic wall shear rates (10,500 s−1) after times of 5 min.[5] Others
have observed that platelet deposition increases with increasing wall shear rate up
to about 10,000 s−1.[29] In parallel plate systems, platelet attachment to a modified
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surface is best for detecting surface area coverage, but is not well suited for vol-
ume growth that requires depth measurements. Further, parallel plate systems have
difficulty exceeding 32,000 s−1 .
Thrombus formation can be optically visualized in a tubular test section with high
spatial and time resolution.[21] The volume growth of thrombus can be clearly seen
as perpendicular to the walls, as compared with the en face view of parallel plates. A
stenosis can be used to create a focal area of very high shear stress that has pathologic
relevance. The focal wall shear rates in a coronary stenosis can be >600,000 s−1 that
is imposed on blood for a physiologic short duration instead of hours to minutes with
a recirculating cone- and-plate or parallel plate system.[4] Occlusion can be verified
by complete cessation of blood flow, a relevant endpoint with catastrophic clinical
consequences. However, the location of platelet-rich thrombus formation within a
stenosis has been difficult to identify, as Schoephoerster et al. and Bluestein et al.
report partial platelet accumulation in regions away from the apical point, while others
such as Badimon and Badimon and Markou co-workers observe thrombus formation
at the apex in the region of highest shear.[2, 6, 27, 30]
Currently, there is a need in the field for a flow- based assay which utilizes high
shear, whole blood and minimal anticoagulation in which thrombus forms to serve as
a point of care system for physicians in an effort to provide better diagnostic care for
patients.[31, 32]
In this article, we measure platelet deposition rates in an in vitro flow system with
high resolution in real time. It is our goal to quantify thrombus formation rates with
high spatial and time resolution in an in vitro system of single-pass blood flow under
conditions of pathologic shear stress in a stenosis. We propose a new method for
creating occlusive thrombosis under very high shear stress for more effective patient
care.
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2.0.3 Experimental Design and Methods
2.0.3.1 Flow Chamber
An in vitro flow system was designed to create very high shear stress in a test section
that could be visualized under a microscope. Whole, porcine blood was perfused
through the test section using a gravity pressure head of 30 mmHg (Figure 1 a). This
single-pass flow-through hemodynamic system is similar to that previously described
by Ku and Flannery.[21]
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Figure 1: (a) Schematic diagram of the in vitro hemodynamic system. Whole blood
flow originates on a raised platform to provide a constant gravity head of 30 mmHg
and flows through a stenotic tube to an open outlet. A pressure transducer is used to
monitor the upstream pressure and a graduated cylinder and stopwatch are used to
measure flow rate. A high resolution digital camera records thrombus formation in the
test section through a low power binocular microscope. (b) Image of an 82% stenosis.
The gradual geometry is characteristic of all stenoses used in these experiments. (c)
Measurement of thrombus volume. Measurements of the thrombus lumen diameter
are taken approximately every 0.17 mm of the outer diameter created by the lumen
of the tube and the inner diameter created by thrombus growth into the tube.
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The stenotic test section (Figure 1 b) created a well- defined location of very high
shear stress, followed by an area of recirculation.[4] The test section was constructed
from glass tubes with an original inside diameter of 1.5 mm. A variety of hour-glass
shaped stenoses were made by a professional glass blower with a severity ranging
from 70 to 83% by diameter. The upstream Reynolds number was between 14 and
130. We have used computational fluid dynamics (CFD) to quantify the shear and
velocity in the stenotic test sections. The glass was coated with fibrillar Collagen Type
I (1 mg/mL, Sigma-Aldrich, St. Louis, MO, prepared according to manufacturers
instructions) within the stenosis section and downstream portions of the tube. The
collagen was left in the tube for 24 h in a warm, moist environment to form a thin layer
of <100 µm. Following incubation, tubes were rinsed with 1x PBS (Fisher Scientific,
Fair Lawn, NJ). Two sets of controls were utilized: (i) those with a stenosis and no
collagen coating and (ii) those without a stenosis and with collagen coating.
2.0.3.2 Whole Porcine Blood
Whole blood from pigs was used for the experiments. Porcine blood was collected
directly from the aorta at an abattoir (Holifield Farms, Covington, GA) and lightly
anticoagulated with 3.5 USP units/mL heparin (Sigma-Aldrich, St. Louis, MO).
This amount of heparin prevented blood clotting in the static upstream reservoir, but
allowed thrombus formation in the flowing test section. For perfusion through the
test section, 250 mL of blood was transferred to a Pyrex jar for each experiment.
During experimenta- tion, blood flowed from PVC plastic tubing (Baxter Healthcare
Corporation, Deerfield, IL) with an inner diameter of 3 mm to the test section. All
porcine blood tests were run within 8 h of harvest. During the flow experiments,
blood was placed on a VSN-5 nutating mixer (Pro Scientific, Oxford, CT) to prevent
blood separation. Mass flow rates were measured using a scale downstream.
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2.0.3.3 Image Processing and Histology
The test section was photographed through a microscope objective using a high resolu-
tion digital CCD camera (Pixelfly, Keleim, Germany) connected directly to the Zeiss
Stemi 2000-C (Zeiss, Jena, Germany) stereo microscope. Images were sequentially
stored at a rate of approximately 0.7 s/frame for off-line analysis. The software
programs for post- processing image analysis were CamWare (Cooke Corporation,
Romulus, MI), Photoshop (Adobe, San Jose, CA), Toast (Roxio, Nevato, CA), and
Matlab (The Mathworks, Natick, MA). The image subtraction provided a quanti-
tative representation of thrombus area vs. stenosis lumen area during thrombosis
progression.
The volume of thrombus can be quantified from the two-dimensional microscope
images (Figure 1 c). The images of thrombus were segmented by the observer and








The length of the thrombus was divided into 11 increments of equal length, L =
0.17 ± 0.015 mm. The outer diameter, DO, was the diameter of the inside of the
glass stenosis and the inner diameter, DI , was the diameter created by measuring
the top of the thrombus growing from the bottom of the tube and the bottom of
the thrombus growing from the top of the tube. By summing the cylinders, the
volume was then integrated along the length of the thrombus. Occlusion was defined
as cessation of flow and is verified by the pressure transducer as an incremental
increase in upstream pressure. Embolus was defined as a rapid increase in pressure
and a sudden stoppage of flow within seconds. Embolus was verified visually and
experiments which terminated with embolus were not included in this study.
Following occlusion, samples were fixed in 10% formalin (Fisher Scientific, Pitts-
burg, PA) overnight. The samples were then dehydrated and fixed in paraffin. 5 µm
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sections were cut longitudinally and placed on a slide until Carstairs staining was
performed.[28] This stain differentiates platelets from fibrin and collagen. Estima-
tions of platelet number were based on a platelet volume of 5 fL and the assumption
that platelets consume 80% of the total thrombus volume.[18, 21]
Some experiments were terminated prior to thrombotic occlusion and the lumen
was perfused with Microfil MV-122 (Flow Tech Inc, Carver, MA), a lead chromate-
based polymerizing contrast agent. The resulting tube was subjected to microcom-
puted tomography imaging (µCT 40; Scanco Medical, Brüttisellen, Switzerland) to
visualize the protrusion of thrombus into the lumen of the stenosis (20 µm voxel
resolution, E = 55kV p, I = 145µA, integration time 200 ms).
2.0.4 Results
2.0.4.1 High Resolution Imaging of Thrombus in a Stenosis
The time-to-occlusion was approximately 17.36 ± 2.62 min (n = 6) for stenoses be-
tween 70 and 83% . In the top Row I of (Figure 2), three example stenoses (a - c)
with varying diameters show that small, focal accumulations of platelets adhered to
the collagen stenosis within the first 40% of experimentation time. The white throm-
bus often accumulated at the down- stream end of the stenoses, but some spots were
visible upstream of the apex.
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Figure 2: Series of photographs demonstrating the growth of thrombus under high
shear stress in varying percent stenoses. Flow is from left to right. (a) A 70% stenosis
by diameter is shown at 4.8, 9.3, and 15.8 min from the onset of flow. (b) A 75%
stenosis by diameter is shown at 5.4, 8.0 and 14.4 min. (c) An 83% stenosis by
diameter is shown at 3.82, 7.9, and 9.8 min.
After the initial focal spotting, thrombus formation appeared more diffuse, causing
a generalized haziness that was concentrated near the apex of the stenosis and down-
stream (Figure 2 Row II). The thrombus accumulation after this time was rapid,
visibly changing in real time. The rapid accumulation was no longer spotty, but
extended both upstream and downstream of the apex for approximately 1 mm. Em-
bolization of platelet aggregates was occasionally observed as a mass of white debris
breaking off from the main structure. The embolic mass was large enough to be
observed optically.
In some samples, the porcine blood would separate downstream of the throat,
causing the high momentum red blood cells to separate from the low momentum
recirculation flow, leaving a clear zone. The clear zone was not stagnant as an embolus
could be seen rotating and the absence of thrombus in the downstream recirculation
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zone was observed. A movie of this unusual hemodynamic phenomenon of a 42%
stenosis can be seen online in the supplemental materials.
Row III of Figure 2 depicts the thrombus extent after total cessation of the blood
flow. Thrombus spanned from wall-to-wall, but some areas devoid of platelets were
occasionally seen. The bulk of the thrombus remained fixed at the apex with little
volume in the downstream recirculation region.
Histologically, the apical thrombus was predominantly composed of platelets (Fig-
ure 3 a). Some red blood cells appeared to be in the downstream region beyond the
platelet mass, likely due to red clot coagulation after cessation of flow. Microcom-
puted tomography provided an alternate view of the lumen and the thrombus surface
before occlusion. In Figure 3 b, the positive casting of the lumen illustrates the
irregular formation patterns of the thrombus surface, with uneven spacing between
thrombus protrusions.
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Figure 3: (a) Flow from left to right: Carstairs staining enables the composition of
the thrombus to be observed. Platelets: gray-blue to navy; fibrin: deep red; red blood
cells: yellow; collagen: bright blue. (b) Microcomputed tomography of the lumen of
a 75% stenosis following partial thrombus growth into the lumen. The image shown
is the shape of the lumen after thrombus has protruded into the flow.
2.0.4.2 Controls
1. Straight tubes were coated with collagen to isolate the independent effects of the
focal stenosis (Figure 4 a). The wall shear rates in these tubes varied between 1000
and 2000 s−1, a physiologic shear range for arteries. A thin layer of platelets attached
to the collagen coated surface after several minutes. Little additional aggregation or
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accumulation occurred after perfusion of 250 mL of whole porcine blood. Thus, rapid
platelet accumulation (RPA) to occlusion appears to require very high shear stress
conditions not present in flow through a straight tube with physiologic shear rates.
Figure 4: Two controls were utilized for this experiment: (a) collagen coated non-
stenotic tubes. (b) Stenotic tube without collagen coating. It can be seen that no
significant deposition forms on either the collagen coated or the stenosis without
collagen. Deposition can be seen as areas stained with analine blue. As the tube is
filled with PBS, some light reflections can be seen in the image.
2. Stenoses with no collagen coating were also used as a control. In these glass test
sections, platelets did not adhere nor aggregate with whole blood perfusion (Figure 4
b). Thus, the collagen coating appears necessary for surface adherence, setting up
the foundation for larger thrombosis.
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2.0.4.3 Thrombus Position
Platelet accumulation was dominant in the throat of the stenosis where shear was
greatest (Figure 5) and all occlusive thrombi occluded within the throat of the steno-
sis. Platelet-rich thrombus consistently formed in locations with high wall shear
stress, such as those regions which reside within 1 mm upstream and downstream
of the apex of the stenosis (p<0.05,n = 6). Dynamic thrombus accumulation in the
lumen creates stenosis values of <80% by diameter that create wall shear rates in
excess of 100,000 s−1. The thrombus continues to grow with total occlusion in the
face of these extreme shear rates.
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Figure 5: (a) This graph shows the fraction of the total diameter filled with thrombus
at occlusion in relation to the apex of the stenosis. (b) This graph illustrates where
the mean deposition of all of the stenotic test sections (n = 6) occurs with respect to
the apex diameter at occlusion, with the average of all of the local stenosis diameters
represented by the gray squares. Taking the mean of all of the inner diameters creates
a representative stenosis that is 81% stenosed by diameter.
2.0.4.4 Thrombus Growth Accelerates to a Larger Rate in Phase II
The volume of thrombus growth is plotted over time, as shown in Figure 6. Thrombo-
sis to occlusion can be broken into two phases: initial thrombus deposition of platelets
to a collagen surface and RPA of platelets away from the surface. The differentiation
of these two phases is further illustrated in Figure 6 b and Figure 7.
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Figure 6: (a) Volume growth of thrombus over time until occlusion for six test
sections. (b) Thrombus growth over time for an 80% stenosis. The initial rate of
platelet deposition can be seen to have a visibly smaller slope (black dashed line)
than the final rate of the half of formation leading to occlusion (RPA, gray dotted
line).
All experiments exhibited initial deposition where few platelets could be observed
at the macroscopic level for several minutes. Thrombus was first optically visible
in the stenoses at 1.2 ± 0.76 min (n = 6). Initial deposition rates measured 3.1 ±
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1.7 ∗ 10−6cm3min−1. At this rate, a 70% stenosis would take approximately 6 h to
completely occlude in the throat.
A second phase of RPA then followed in which mural thrombus grew rapidly. The
RPA rates were significantly greater than the initial deposition rates, averaging 7.8
± 3.5 µm3 µm−2 min−1 (20 ± 4.5 ∗10−6 cm3 min−1 with an average surface area of
2.9 ± 1.1 ∗ 106µm2, p<0.05, n = 6, Figure 7), with all occlusions occurring in <20
min (Figure 6 a). Our maximum RPA deposition rate of 13.7 µm3 µm−2 min−1 (15.1
∗10−6 cm3 min−1 in an 81% stenosis with an original surface area of 1.1 mm2) is
almost twice this.
Figure 7: Initial deposition and rapid platelet accumulation formation rates in cm3
∗10−6min−1, n = 6. RPA (20±4.5∗10−6cm3min−1) is significantly faster than initial
deposition (3.1 ± 1.7 ∗ 10−6cm3min−1, p <0.05).
2.0.4.5 Intersection Determined Initial Deposition and RPA: Another Method
for Calculating Rates
To serve as a check for the initial deposition rates and the RPA rates, we compared
the intersection of the regression lines created for both of the rates. The regression
lines for initial deposition and RPA of each stenosis intersected at 7.6 ± 3.6 min
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(n = 6), serving as a second method for dividing the initial phase of deposition from
the second phase of RPA (Figure 8). Using the intersection time of the lines as a
dividing point, initial deposition was 5.5 ± 3.0 * 10−6 cm3 min−1 and RPA growth
was 18 ± 7.7 ∗ 10−6 cm3 min−1 (p<0.05, Table 1).
Figure 8: Regression lines describe a change in the rate of thrombus growth during
initial deposition and rapid platelet accumulation. The intersection between the two
lines occurred at approximately 7.6 min.
RPA rates determined using either the intersection definition or the last 50% of
total thrombus volume, were similar (p>0.05, n = 6, Table 1). RPA accounts for the
bulk of thrombus formation (77%). The slightly lower rate of RPA calculated using
the intersection method could indicate some inclusion of the transition from the slow
initial adhesion.
Using the intersection definition, initial deposition was greater than the initial
deposition measured using the rate of formation to first visible thrombus (p<0.05,
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Table 1: The percentage of final thrombus volume included in each definition of
initial deposition and RPA as well as their respective rates of growth. It can be seen
that initial deposition is faster than RPA when measured as first visible thrombus vs.
last 50% of final thrombus volume (a, n = 6, p<0.05) as well as first 7.6 min vs. last
7.6 min (b, n = 6, p<0.05).
Percentage of Final Rate of Growth
Thrombus Volume (∗10−6cm3min−1)
Initial deposition (first visible thrombus) 3.3 ± 3.0% 3.1 ± 1.7a
Initial deposition (intersection) 19 ± 10% 5.5 ± 3.0b
Rapid platelet accumulation (last half) 48 ± 6.9% 20 ± 4.5a
Rapid platelet accumulation (last half) 48 ± 6.9% 20 ± 4.5b
n = 6). The intersection definition included the initial 19±10% of thrombus volume,
whereas deposition to first visible thrombus included only 3.3 ± 3.0% of the final
thrombus volume. It is possible that the intersection definition includes some RPA
growth, thereby increasing the initial deposition rate.
In our in vitro system, platelets pass through the stenosis only once. CFD calcula-
tions show that the velocity of platelets in the throat of the stenosis generally exceeds
1 m/s. The transit time of a platelet through the 2 mm stenosis would then be about
2 ms. This transit time is much too short for activation of the circulating platelet and
is far below the threshold for shear-dependent activation. The CFD model quantifies
the wall shear over the thrombus as reaching over 100,000 s−1 for all test sections
described in this article.
2.0.5 Discussion
Our studies demonstrate that thrombus growth can be followed with high spatial and
time resolution in an in vitro system of single-pass porcine blood flow under con-
ditions of pathologic shear stress. Millions of platelets deposit within a stenosis to
occlusion with local wall shear rates exceeding 100,000 s−1. After an initial delay,
RPA occurs with rates averaging 7.8±3.5µm3µm−2min−1 (20±4.5∗10−6cm3min−1).
With occlusion times of approximately 20 min and maximum deposition rates of
27
13.7µm3µm−2min−1, the in vitro stenosis model is consistent with clinical observa-
tions of sudden cardiac ischemic death in under an hour.[11]
Our maximum deposition rate of 13.7µm3µm−2min−1 (15.13∗10−6cm3min−1) ex-
ceeds those found by previous reports.[1, 3, 5] The lowest rate, 0.5µm3µm−2min−1,
measured by Alevriadou, occurred at the lowest wall shear rates (1500 s−1) and
shortest experimentation times (2 min).[1] Badimon and Barstad measured maximal
deposition rates of 8 and 12 µm3µm−2min−1, respectively, by increasing experimen-
tation times to 5 min with high wall shear rates.[3, 5] By utilizing both very high,
pathologic shear (100,000 s−1) and longer timescales (>5 min), we were able to mea-
sure a maximum deposition rate which is on the high end of those previously reported.
RPA in our single pass, stenosis system exceeds Barstad et al.s maximum deposition
at 10,000 s−1 by only 1.3 µm3µm−2min−1, indicating that platelets may accumulate
in this rapid fashion once a threshold wall shear rate has been reached.
Contrary to results found by Schoephoerster et al. in a canine model where
maximal platelet counts were assigned to the recirculation region downstream of the
throat, thrombus formation was optically visible in the throat of the stenosis with
the maximum platelet deposition within 1 mm of either side of the throat apex.[6]
This indicates that platelet aggregation occurs around the highest shear in the steno-
sis model. Wootton found similar results in an un-anticoagulated, ex vivo baboon
model, with thrombus forming at the apex of the stenotic test section.[30] Schoepho-
ersters utilization of a swab sampling technique may not provide a precise location of
mural thrombus, and their Lexan surface may be different from our collagen coated,
glass stenosis model. Platelet accumulation in a murine model has been observed by
Nesbitt et al. at the apex that may be pushed into the recirculation zone as the apex is
quite short.[23] We also observed some migration of thrombus off the apex toward the
downstream recirculation zone in the early phases of thrombus formation. Further ex-
perimentation will be pursued utilizing varying whole blood hematocrit that can alter
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collision frequency and viscosity to determine shear effects on platelet margination.
This stenosis model creates a new and clinically relevant endpoint of visual occlusion
for in vitro studies with physiologic Reynolds numbers. Many current in vitro shear
systems utilize a parallel plate chamber pioneered by Hellums et al. in the 1990s,
the cone-and-plate viscometer, or the PFA-100.[9, 14, 15, 17, 26, 31, 32] A benefit
of the stenosis model over these systems is that the geometry of the test section al-
lows for continuous observation of thrombus formation until occlusion. Parallel plate
chambers utilize a different aspect ratio for the test section: wide and long, but very
shallow in depth. The perpendicular depth of field prevents accurate measurements
of plateletplatelet accumulation beyond the first few layers of platelet deposition. The
abrupt geometry of the parallel plate chamber corners may also influence deposition
rates through alteration of the test section hemodynamics. Cone-and-plate systems
expose blood for very long periods of high shear. The PFA-100 provides only a binary
output without control of shear or continuous monitoring of the thrombotic process.
While flow occlusion has been noted in animal studies, the opaque arteries do not
allow visualization of the growing thrombus without the use of contrast or magnetic
resonance imaging.[2, 7] The in vitro model described here allows for greater control
of the blood sample and test section geometry, with quantitative measurement of
thrombus thickness, thrombus shape, and time-to-occlusion.
Recent independent evidence supports the hypothesis that platelet adhesion and
aggregation at very high wall shear rates may be different from the shear-dependent
adherence at moderate shear. Ruggeri et al. have described parallel plate experiments
in which platelet adhesion (but not occlusion) in human blood remained high with
PGE treatment or blockade of αIIbβ3 adhesion was abolished by blockade of GPIb
with monoclonal antibodies for very high wall shear rates of 20,000 s−1.[25] Nesbitt
et al. also reported that the adhesion of the initial hundred platelets is not prevented
by PGE or antibodies to αIIbβ3, but is completely blocked by antibodies to GPIb
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in a mouse capillary model.[23] Our studies indicate that the platelet transit time of
2 ms is far too short for activation of circulating platelets, but that the lag time of
several minutes to RPA may be facilitated by activation by high shear on the mural
platelets. Further identification of the mechanisms of high shear occlusion could lead
to treatments that prevent RPA without blocking homeostatic hemostasis.
Our hemodynamic whole, porcine blood system has several limitations. The use
of a single-pass flow-through system requires a large volume of blood. A smaller
in vitro setup should be pursued for future experimentation on human blood. 3-D
volumetric extrapolations of 2-D measurements are also problematic due to distortion
and circumferentially non-uniform deposition of thrombus. This may be mitigated
in the future with the use of a glycerin bath for the Pyrex stenosis and correlation
between micro-CT and image measurements. As a separate check, the thrombus
volume in the throat was compared with cylindrical volumes for the maximum and
minimum diameters at the ends and middle of the hourglass shapes thrombus. For
a representative thrombus, the maximum cylinder had a volume of 0.62 mm3, the
measured thrombus volume was 0.35 mm3, and the minimum cylinder was 0.20 mm3.
Thus, the measured thrombus volume appears reasonable even in the face of optical
refraction of index changes. Current measurements of error in the throat of the
stenosis, however, show the error to be approximately 10%. The edges of the stenosis
show the greatest error, which will be found in the initial adhesion measurements,
or the first 5.0 ± 3.2 ∗ 10−6cm3. The choice of heparin for baseline anticoagulation
may affect platelet function and the local concentration of thrombin.[12] Heparin
may decrease platelet affinity and weaken the thrombus, making it more likely to
embolize.[12, 16] Our heparinization rate of 3.5 USP units/mL was determined to be
the minimum heparinization that would allow for the blood to be transported back
to the laboratory and experiments to be completed without coagulation occurring.
Markous ex vivo baboon model of thrombosis measured deposition rates of 0.9
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billion platelets cm−2min−1 which, using a platelet volume of 5 fL, converts to 0.75
µm3µm−2min−1, indicating that these light anticoagulation methods are not prevent-
ing platelets from reaching their maximal deposition rates.[18, 20] These differences
in maximum platelet deposition rates may be attributed to variances in species as
both Alevriadou and Barstad utilize human blood while porcine blood is used in
the Badimon model and Markou uses a baboon model. Occlusion rates were never
stated in the Markou model and occlusion was defined as cessation of flow before 2
h.[18, 20] The walls of the stenosis are rigid, unlike compliant, healthy arteries. How-
ever, arteries in diseased patients are also more rigid, therefore making compliance
less important for modeling diseased artery hemodynamics.
2.0.6 Conclusion
In conclusion, we quantify the volume and rate of intravascular thrombosis under
pathologically high shear conditions of a focal stenosis over 100,000 s−1. The throm-
bosis proceeds to occlusion in 17 ± 2.6 min (n = 6) from the rapid accumulation
of 44 million platelets. Average RPA rates 7.8 ± 3.5µm3µm−2min−1 (20 ± 4.5 ∗
10−6cm3min−1) in these experiments are significantly greater than initial deposition
rate 1.1 ± 0.49µm3µm−2min−1 (3.1 ± 1.7 ∗ 10−6cm2min−1) in 70 to 83% stenoses
(p<0.05, n = 6). During RPA, platelet-rich thrombus forms at the apex of the steno-
sis where the shear remains the greatest but not in the large recirculation region
further downstream. The capture of circulating platelets occurs on a very short time
scale of <2 ms, much shorter than the time scale for activation in the single-pass
system. This in vitro model of rapid capture of millions of platelets from whole,
porcine blood can be used to study the mechanisms of thrombotic occlusion under
arterial hemodynamics as well as be applied in a clinical setting to improve patient
treatment by studying dose responsiveness, individual blood differences for person-
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A LOW-VOLUME, SINGLE PASS IN-VITRO SYSTEM TO
STUDY HIGH SHEAR THROMBOSIS WITH HUMAN
BLOOD
3.0.8 Introduction
Thrombus formation contributes to myocardial infarction (MI) and stroke, the lead-
ing causes of death in developed countries. Following plaque rupture, platelets ini-
tially adhere to the damaged arterial subendothelium in the region of very high shear
stress and subsequently, rapidly accumulate to previously adhered platelets, a process
known as thrombosis. We have recently described a phenomenon of Rapid Platelet
Accumulation (RPA) whereby millions of platelets accumulate per minute that can
lead to occlusion and mortality within an hour after symptomatic onset of MI.[3, 11]
This is in strong contrast to common platelet adhesion studies in parallel plate sys-
tems whereby surface area coverage of hundreds of platelets over 5 minutes is the
typical endpoint.[15]
As mortality occurs quickly, due to RPA, patients experiencing MI are often
treated based on general evidence.[4] Unfortunately, not every patient is respon-
sive to common treatments, with some patients being aspirin resistant and others
being Plavix R© resistant, the leading prescribed pharmaceutical for patients with
atherosclerosis.[6, 19] This being the case, it is necessary to develop a device which
utilizes low volumes of human blood (30mLs) in which RPA can be measured. This
device would be single pass to ensure that platelets are not activated prior to experi-
encing the region of high shear stress, and have a pathologically similar, smooth tran-
sition to the region of highest shear. The goal of our study is to create an apparatus
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that uses low volumes of whole blood in which RPA occurs as well as directly com-
pare any species differences existing between porcine and human blood with regard to
thrombus formation morphology, composition and RPA. If successful, this device may
be used to analyze human blood samples and contribute to patient-specific therapy
creation.
As such, it is important to review previous hemodynamic systems which have been
used to study platelet accumulation.
3.0.8.1 Aggregometry
Clinically, it is important to utilize low volumes of blood to test platelet accumulation
as 100mLs is approximately the largest amount of blood which can be collected from
a patient on a routine basis. The VerifyNow aggregometer utilizes very low (2mLs)
volumes of blood to test patient specific response to different platelet receptors.[9]
However, VerifyNow R© does not utilize shear conditions such as those found patho-
logically. Shear rates in diseased arteries are very high (1,500s−1 - 100,000+s−1)
compared to those seen physiologically (<1,500s−1).[11, 12] As large proteins, such
as von Willebrand Factor (vWF), which contribute to thrombosis behave differently
under increased shear rates, high shear is an important factor to studying RPA.[7]
3.0.8.2 Cone and Plate Viscometer
Cone and plate viscometers utilize small volumes of blood and very high shear stress.
However, the cone and plate viscometer subjects the blood to continuously high shear
rates that can activate all of the platelets.[5] This does not allow for a physiologically
similar response, as platelets in the body are not exposed to a sustained, pathologically
high shear. The advantage of a single pass system is that platelets are only exposed
to the critical shear region a single time.
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3.0.8.3 PFA-100 R©
A low volume, high shear (>5,000s−1), single pass system currently used to test
platelet dysfunction clinically is the PFA-100 R©.[1] In the system, blood is pulled
through a capillary and over an undefined internal membrane. It is unclear whether
the closure time listed is definitively time to thrombotic occlusion or potentially em-
bolic occlusion of the membrane. The short closure time of 5 minutes may also not
be long enough for RPA to occur.
3.0.8.4 Parallel Plate
Parallel plate models utilize low volumes of blood, high shear, single pass and opti-
cal measurement. Due to an en face view of the chamber during experimentation,
measurement of subsequent platelet-to-platelet deposition characteristic of millions
of platelets is quite difficult, with some experiments terminating after 5 minutes
measuring only hundreds of platelets.[15] Even with fluorescence, measurement of
platelet-to-platelet deposition is only possible until saturation, after which additional
fluoresence cannot be measured. Further, the parallel plate model utilizes a wide
aspect ratio that is not anatomic, creating unusual secondary flows in the corners of
the chamber.
3.0.8.5 Stenosis Model
The stenosis model created by Flannery and Ku utilizes single pass flow, measures
optically from RPA to occlusion, and creates a region of very high, pathologic shear
stress in a smooth, rounded stenosis which mimics the shape of an atherosclerotic
plaque.[8] The stenosis is approximately 2mm in length, creating an anatomically
similar shear region to that of a coronary or carotid stenosis. While advantageous due
to a defined, very high, pathologic shear region and anatomic similarity to a carotid
stenosis, the stenosis model requires 240mLs of blood for each experiment.[8, 11] This
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assay has only been tested with porcine blood due to porcine’s pathological similar-
ities and suitability as a direct comparison to human blood for ex-vivo coagulation
studies.[8, 14, 16, 17, 20] However, faster clot formation times for porcine blood than
human blood have been shown.[10, 17] This may indicate the requirement of more
than 240mLs for experimentation with humans when utilizing this system which is
unacceptable when considering a patient may need multiple tests conducted.
To this end, a low volume (30mLs), high shear stress (>3,500 s−1), single pass,
constant volume, glass capillary model of occlusive thrombosis which utilizes whole
blood for experimentation has been created. It is the aim of this syringe pump
apparatus to achieve RPA using low volumes of whole human blood. Thrombus
formation morphology, initial formation rates, RPA rates and thrombus composition
will be measured and compared to porcine blood.
3.0.9 Experimental Design and Methods
3.0.9.1 Experimental Setup: Gravitationally Fed and Syringe Pump Apparatuses
The gravitationally fed, single pass system was run as previously described, with
240mL of porcine blood flowing through PVC plastic tubing (Baxter Healthcare Cor-
poration, Deerfield, IL) with an inner diameter of 3 mm to the test section from a
raised platform, past a pressure transducer and through a collagen coated stenosis
(Figure 9 A).[8, 11] Mass flow rates were measured using a scale downstream.
A syringe pump fed, in-vitro flow system (Figure 9 B) was designed to create high,
pathologic shear rates (3,500s−1), exceeding shear induced platelet activation, in a test
section that could be visualized under a microscope.[2] Whole, lightly heparinized (3.5
IU/mL) blood was perfused past a pressure transducer (Harvard Apparatus, South
Natwick, MA) and through a transparent, pyrex test section using a syringe pump to
maintain constant flow. For porcine blood experiments, 30mLs of whole blood was
used. Human blood experiments also did not exceed 30mLs.
During the flow experiments, excess blood was placed on an Orbit LS orbital mixer
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Figure 9: (A) Gravitationally fed experiments required an initial 240mLs of blood
to be placed on a platform 30cm above the stenosis. During experimentation, blood
flowed from the raised platform, past a pressure transducer, through the collagen
coated test section and onto a scale where mass flow measurements were taken in
real time. (B) The syringe pump experiment required a maximum of 30mLs of blood
for experimentation to occlusion. Blood flowed, driven by a syringe pump, from a
syringe, past a pressure transducer and through the collagen coated test section. Both
systems are single pass.
(Labnet, Woodbridge, NJ) to prevent blood separation. All blood was used within 8
hours of harvest.
The test section was constructed from glass tubes with an original inner diameter
of 1.5mm. A variety of hour-glass shaped stenoses were made by a professional
glass blower with a severity ranging from 75 to 92% (n = 34) by diameter for all
experiments with initial flow rates between 0.04 mL/min for highly stenosed test
sections and 1.1mL/min for the larger diameter test sections.






where d is the smallest inner diameter in the test section and γ̇ is 3,500 s−1. Shear
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rates were highest at the throat of the stenosis and not upstream.
3.0.9.2 Collagen Coating
Stenoses were coated with fibrillar Collagen Type I (1 mg/mL, Sigma-Aldrich, St.
Louis, MO, prepared according to manufacturer’s instructions). The collagen was
left in the tube for 24 h in a warm, moist environment to form a thin layer of <100
m. Following incubation, tubes were rinsed with 1x PBS (Fisher Scientific, Fair Lawn,
NJ).
3.0.9.3 Whole Porcine Blood/ Whole Human Blood
Whole porcine blood was collected directly from the aorta at an abattoir (Holifield
Farms, Covington, GA). Whole human blood from donors was obtained at the Georgia
Institute of Technology Phlebotomy Lab at Stamps Health Services in accordance
with the IRB (Protocol H06190). Blood was drawn from a 21G butterfly needle
directly into a syringe.
3.0.9.4 Image Processing and Histology
The test section was photographed through a 2x microscope objective using a high
resolution digital CCD camera (Pixelfly, Keleim, Germany), with a 0.5x magnifica-
tion, connected directly to the Zeiss Stemi 2000-C (Zeiss, Jena, Germany) stereo
microscope as previously described.[11] Images were sequentially stored at a rate of
approximately 1 s/frame for off-line analysis. The software programs for postprocess-
ing image analysis were CamWare (Cooke Corporation, Romulus, MI) and Photoshop
(Adobe, San Jose, CA).
Embolus was defined as a rapid increase in pressure and a sudden stoppage of flow
within seconds. Embolus was verified visually and experiments which terminated with
embolus were not included in this study.
As lower volumes of blood were used, RPA and not occlusion was used as an
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endpoint, although it is reasonable to assume that occlusion would occur with addi-
tional blood. Rapid Platelet Accumulation (RPA) was defined as being any platelet
deposition rate greater than 1.6 µm3 µm−2 min−1 (the upper bound of the average
initial deposition, [11]) and occlusion is defined as a pressure head of P = 30mmHg for
syringe pump experiments. Deposition rates were calculated by taking a regression
of consecutive time points during thrombus formation.
3.0.9.5 Statistics
All experiments were analyzed using an unpaired student’s t-test where statistical
significance is defined as p<0.05.
3.0.10 Results
Platelet deposition morphology, thrombus composition, initial platelet deposition
rates and RPA are analyzed in the human syringe pump model using low volumes
of blood (<30mLs). These are compared to previous results obtained using porcine
blood in the gravitationally fed model and the syringe pump model. Species differ-
ences between human blood and porcine blood are also compared.
3.0.10.1 Human Syringe Pump Model
Thrombus formation to complete occlusion can be seen in the human blood syringe
pump model. Initial visible adhesion (Figure 10 A), or the first noticeable platelet
deposition, is minimal and occasionally located downstream. Some spots of thrombus
deposition form upstream or within the throat of the stenosis.
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Figure 10: Thrombus formation using human blood in an 86% stenosis. Initial
visible formation in this stenosis is seen as very slight formation which occurred in
5.4 minutes (A) and is highlighted by the green box. Following initial formation,
subsequent platelet deposition occurs (B) until complete occlusion (C).
Following visible initial adhesion, thrombus deposition became more diffuse, with
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platelets forming finger-like projections into the flow (Figure 10 B). Platelets de-
posited rapidly onto this surface, showing visible morphological changes in real time
until occlusion (Figure 10 C).
Histological staining of human thrombus in the syringe pump apparatus reveals
that it is composed predominantly of platelets (Figure 11). Red blood cells are
trapped downstream of the occlusive plug and some small pockets are trapped within
but do not contribute to the bulk of the platelet-rich thrombus plug (Figure 11).
Figure 11: Human thrombus stained using Carstairs staining highlights platelets in
navy blue. It can be seen from this stain that an occlusive thrombus formed from
human blood is predominantly platelets.
Platelet deposition to occlusion in human blood in the syringe pump model occurs
in two phases: initial visible adhesion, which is the rate at which the first deposition
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of platelets to the thrombogenic surface occurs. This is followed by RPA, a fast
regime of platelet-to-platelet deposition, which precedes occlusion (Figure 12). Prior
to initial visible adhesion, there is a lag time of 7.4 ± 3.8 min and requires 3.1 ±
2.0mLs to occur (n=21). This constitutes the deposition of the first 5.7 ± 7.0 ∗ 10−6
cm3 of thrombus volume (n=21).
Figure 12: Human blood deposits in the stenosis in two phases -initial visible forma-
tion followed by a faster Rapid Platelet Accumulation.
Initial deposition occurs at rates of 0.8 ± 1.0 µm3 µm−2 min−1 (n=21, Figure 13).
This is significantly slower than RPA which occurs at rates of 4.5 ± 2.4 µm3 µm−2
min−1 (n=21, p<0.05).
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Figure 13: Thrombus deposits significantly slower during visible initial deposition
(p<0.05) than RPA. The mean is denoted with a black circular dot and outliers are
marked with an ∗.
The disparity between the two rates can also be seen in the full range of values
(Figure 14), with the mean of initial visible adhesion below the lowest value of RPA
and only 5/21 data points above the mean.
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Figure 14: Thrombus deposits significantly slower during visible initial deposition
(p<0.05) than RPA.
3.0.10.2 Porcine Syringe Pump and Porcine Gravitationally Fed Experiments
Thrombus deposition to occlusion occurred similarly in porcine experiments. Follow-
ing initial visible adhesion, thrombus deposited throughout the throat of the stensosis
(Figure 15 AI, BI). Subsequent platelet-to-platelet deposition filled the throat of the
stenosis until occlusion of the lumen (Figure 15 AII, BII).
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Figure 15: Porcine blood forms similarly in both the syringe pump (A) and the grav-
itationally fed (B) models. Following visible initial adhesion, more diffuse deposition
(I) and, ultimately, occlusion occur (II).
For both the gravitationally fed and syringe pump models, thrombus formation
occurred in the throat of the stenosis, where shear was highest.
Histological staining of occlusive thrombus of porcine blood in both the syringe
pump model (Figure 16 B) and the gravitationally fed model (Figure 16 A) showed
that thrombus was composed mainly of platelets. Red blood cells can also be seen in
the sample (stained as red), likely trapped after flow cessation.
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Figure 16: Thrombus formation in both the gravitationally fed (A) and syringe pump
models (B) are dominated by platelets (navy) in porcine blood. Platelets are stained
using Carstairs Staining protocol and flow during formation was from left to right.
The scale for both samples is indicated above.
3.0.10.3 Comparison of Human and Porcine Models
The amount of blood to occlusion was 43 ± 24mLs (n=6) for the porcine gravita-
tionally fed experiments. A significantly lower amount of blood, 6.1 ± 2.7mLs was
required for occlusion for the porcine syringe pump model (p=0.05, n=7).
In the porcine gravitationally fed model, visible initial formation, the first mea-
surable thrombus volume, is 5.0 ± 2.0∗10−6cm3. In the porcine syringe pump model,
visible initial formation is 3.8 ± 3.6 ∗10−6cm3. In the human syringe pump model,
visible initial formation is 5.7 ± 7.0 ∗ 10−6cm3.
Visible initial formation occurs within 1.3 ± 0.8mLs in the pocine syringe pump
(n=7) and within 3.1 ± 2.0mLs for the human syringe pump model (n=21, Table 2).
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Table 2: Initial visible formation occurred significantly faster in the porcine gravi-
tationally fed model than either the porcine syringe pump model (γ,p<0.05) or the
human syringe pump model (β, p<0.05). The porcine syringe pump model formed
initial visible formation significantly faster than the human syringe pump model (α,
p<0.05).
Amount of Blood to Amount of Time to
Visible Initial Visible Initial N
Formation (mLs) Formation (min)
Human Syringe Pump 3.1 ± 2.0 7.4 ± 3.8α,β 21
Porcine Syringe Pump 1.3 ± 0.8 2.7 ± 0.5α,γ 7
Porcine Gravitationally Fed 3.9 ± 3.2 1.0 ± 0.9β,γ 6
A similar volume of blood is required for visible initial formation in the porcine
gravitationally fed model (3.9 ± 3.2mLs, n=6). Due to the different initial flow rates of
the models, with gravitationally fed being faster than constant volume, visible initial
formation occurs significantly faster (1.0 ± 0.9 min) in the porcine gravitationally
fed model (p<0.05) than both the porcine syringe pump model (2.7 ± 0.5 min) and
human syringe pump model (7.4 ± 3.8 min, Table 2). The porcine syringe pump
model also forms visible initial formation significantly faster than the human syringe
pump model (n=7, n=21, p<0.05).
In the porcine gravitationally fed model (10 ± 3.5 µm3 µm−2 min−1, n=5) and
the porcine syringe pump model (9.6 ± 6.1 µm3 µm−2 min−1, n=7), Rapid Platelet
Accumulation (RPA) rates are significantly higher than the human syringe pump
model (4.5 ± 2.4 µm3 µm−2 min−1, n=21, p<0.05, Figure 17). The maximum RPA
rate for the porcine gravitationally fed model is 15 µm3 µm−2 min−1 and the porcine
syringe pump model is 17 µm3 µm−2 min−1, while the human syringe pump model
had a maximum RPA rate of 12 µm3 µm−2 min−1.
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Figure 17: Rapid Platelet Accumulation Rates in the human syringe pump model are
significantly lower (p<0.05, n=21) than either the porcine gravitationally fed model
(n=6) or the porcine syringe pump model (n=7).
While the RPA rates for human blood is slower than that for porcine blood,
there is a minimal difference between visible initial formation rates for the porcine
gravitationally fed model (1.1 ± 0.5 µm3 µm−2 min−1) and the human syringe pump
model (0.8 ± 1.0 µm3 µm−2 min−1).[11]
3.0.11 Discussion
Our studies demonstrate that thrombus formation to RPA occurs in a low volume
(<30 mLs), single pass, syringe pump fed system using whole, human blood. RPA
occurred in the syringe pump with human blood following the first 7.4 ± 3.8 min
(n=21) and averaged 4.5 ± 2.4 µm3 µm−2 min−1 (n=21) with a maximum of 12
µm3 µm−2 min−1. Thrombus formation morphology was similar as was composition
of occlusive thrombus between species, with thrombus consisting of predominantly
platelets for both porcine and human models. Porcine blood had a shorter time to
initial formation, with visible thrombus occurring within 2.7 ± 0.5 min (n=7, p<0.05)
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of experimentation for the syringe pump model. Porcine RPA was also faster in the
porcine syringe pump model (9.6 ± 6.1 µm3 µm−2 min−1, n=7, p<0.05) than the
human syringe pump model 4.5 ± 2.4 µm3 µm−2 min−1 (n=21). However, the rate
of visible initial formation in the human syringe pump model (0.8 ± 1.0 µm3 µm−2
min−1) is similar to the porcine gravitationally fed model (1.1 ± 0.5 µm3 µm−2
min−1).[11]
Differences in harvesting methods between porcine and human blood may account
for differences in RPA rates in this syringe pump model. Pigs may release more
stress hormones such as epinephrine during slaughter, creating a more thrombogenic
blood than humans, who experience minimal stress during a routine blood draw.
Alternatively, differences in desposition rates may simply be due to species differences.
The human blood, syringe pump model presented here utilizes very high shear
rates seen pathologically (>3,000s−1 ), which are not used in clinical aggregometry
such as the VerifyNow R©. Longer experimental times (>10min) are also utilized.
Models such as the PFA-100 R© and parallel-plate chambers terminate with experi-
ments 5 minutes or less. Since human blood has a lag time of 7-10 min until RPA, it
is unlikely that the PFA even tests for the pathologic platelet accumulation respon-
sible for intravascular thrombotic occlusion.[15] The syringe pump model also uses
a stenotic test section which exposes platelets to a region of high shear stress. The
cone and plate viscometer subjects platelets to a sustained, high shear rate, which
is non-physiologic. A model encompassing all of these requirements for high, patho-
logic shear, lengthened experimental times and a geometry which transiently exposes
platelets to shear is the Flannery-Ku stenosis model.[8] However, due to its large
requirement for blood (240mLs), makes it prohibitive as an assay for patient-specific
testing.
Our human blood, single pass, syringe pump experiment has limitations. The first
is the lack of physiologic pulsatility. Previous reports are inconclusive, suggesting
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that there is either no change in thrombus growth or an increase in thrombus growth
caused by pulsatility.[18, 21] Furthermore, most studies of pulsatility focus on initial
deposition and do not explore pulsatile effects on platelet-platelet deposition.[13] This
should be pursued in future experimentation using whole, human blood.
Another limitation is that the walls of the stenosis are rigid, unlike compliant,
healthy arteries. However, atherosclerotic arteries are also more rigid, making com-
pliance a minimal consideration for modeling the diseased hemodynamics.
3.0.12 Conclusions
In conclusion, we have created a steady, single pass model of RPA using low volumes
(<30mLs) of whole, human blood which may be used for patient-specific testing.
The human syringe pump model was developed following the reduction of the 240mL
porcine gravitationally fed model of RPA to a low volume, syringe pump fed model
of RPA also using porcine blood. As both models formed RPA using porcine blood
at similar rates, 10 ± 3.5 µm3 µm−2 min−1 (n=6) for the porcine gravitationally fed
and 9.6 ± 6.1 µm3 µm−2 min−1 (n=7) for the porcine syringe pump model, and with
similar morphologies, we were able to transition the model to utilize human blood.
In the human syringe pump model, visible initial formation occurs in the first 3.1
± 2.0 mLs when perfused through stenoses ranging from 75% to 92% at an initial
shear rate of 3,500s−1. For this initial stage, platelets deposit at a rate of 0.8 ± 1.0
µm3 µm−2 min−1, similar to rates in the porcine gravitationally fed model (1.1 ± 0.5
µm3 µm−2 min−1, n=21). RPA rates in human blood are less than those of porcine
blood (9.6 ± 6.1 µm3 µm−2 min−1, n=7), with human RPA rates measuring 4.5 ±
2.4 µm3 µm−2 min−1 (n=21).
This whole, human blood model of RPA can be used for future clinical use to
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CHAPTER IV
PREVENTING RAPID PLATELET ACCUMULATION IN
WHOLE, HUMAN BLOOD UNDER HIGH SHEAR
STRESS BY BLOCKING αIIBβ3 AND PLATELET
ACTIVATION
4.0.14 Introduction
Intravascular thrombosis is arguably responsible for the highest percentage of mor-
bidity and mortality in the developed world. Death by Myocardial Infarction (MI)
or stroke due to thrombosis can occur within an hour of symptomatic onset.[10]
Platelet accumulation to occlusion under high shear rate conditions causes most arte-
rial thrombosis and occurs in two phases - an initial adhesion of platelets to the dam-
aged subendothelium followed by Rapid Platelet Accumulation (RPA) where platelets
adhere to other platelets, ultimately rapidly stopping blood flow.[21] Platelet throm-
bosis typically occurs in arteries in the regions of high shear stress.[12] Pathologically
high shear rates are present in the arterial system when an atherosclerotic plaque
creates a local stenosis. Stenoses greater than 25% in arteries can create shear rates
exceeding 3,500s−1 that reach over 100,000s−1 as thrombus grows.[3] Previous studies
indicate that, following initial platelet adhesion onto a thrombogenic surface in these
high shear rate regions, platelet activation ensues.[9] Activation of the platelet causes
a conformational change in Glycoprotein IIb/IIIa (αIIbβ3) which allows αIIbβ3 to bind
other proteins and occurs through a multitude of pathways.[9]
Anti-platelet agents are therefore one approach to prevent thrombosis causing MI
and stroke. Clinical studies of the efficacy of anti-platelet agents have been mixed,
with some agents demonstrating more blockade than others. Acetylsalicylic Acid
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(ASA, aspirin) is the most widely used therapy in patients with vascular disease
due to its relative cheapness and effectiveness.[1] ASA functions by preventing the
metabolism of arachadonic acid to thromboxane A2. Thromboxane A2 promotes
platelet activation.[17, 25] Clopidogrel (Plavix R©) is another popular pharmaceutical,
seen by some as superior to ASA.[11] It prevents activation by competitively and
irreversibly binding to P2Y12, an ADP receptor.[27] Prostaglandin E1 (PGE1), yet
another activation inhibitor, prevents activation by increasing cyclic-AMP which de-
creases Ca2+ rise in the cytoplasm and ultimately stabilizes the platelet membrane.
Even though these treatments have an effect on thrombosis, there is still contro-
versy as to the role of platelet activation under high shear stress. Recent studies
by Ruggeri et al. indicate that platelet aggregation of <100 platelets is activation
independent.[22] As there is success with activation inhibitors clinically, large scale
thrombus formation may require activation.
Inhibiting the change in conformation of αIIbβ3 to its active form, a protein trig-
gered by platelet activation, specifically may prevent platelet aggregation.[4] The most
widely used inhibitor of αIIbβ3 activation is abciximab (Reopro
R©), a Fab fragment
directed against αIIbβ3.[20] Eptifibatide (Integrilin
R©), another inhibitor of αIIbβ3, is
a cyclic heptapeptide which reversibly binds the glycoprotein.[5, 7]
Patients do not have uniform response to these pharmaceuticals, with therapy-
resistant patients having an increased risk of cardiovascular events.[24] This creates
the need for a low-volume device which allows for patient-specific therapy testing.
Under pathologic high shear rate conditions, we have previously shown that platelets
in whole blood can attach in large numbers on a collagen-coated surface causing rapid
platelet accumulation (RPA) rates greater than 1.6 µm3 µm−2 min−1. In our in-vitro
hemodynamic assay, hundreds of millions of platelets attach in the throat of the
stenosis during RPA, eventually causing total occlusion of blood flow in less than
30 minutes. To this end, a low volume (30mLs), high shear stress, capillary model
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of RPA which utilizes whole, human blood for experimentation may be utilized for
testing patient specific therapies.
The purpose of this study is to determine if current anti-platelet agents are effec-
tive inhibitors of thrombosis under high shear conditions in whole, human blood. Our
hypothesis is that the mechanism of the anti-platelet agent influences the efficacy and
uniformity of blockade in human blood. Thus, we test five different pharmaceuticals
(PGE1, ASA, 2-MeSAMPS, abciximab, and eptifibatide) on their ability to block
thrombus growth in stenotic test sections.
4.0.15 Experimental Design and Methods
4.0.15.1 Syringe Pump Apparatus
A single pass, syringe pump fed, in-vitro system was created in which thrombus
formation could be viewed under a microscope (Figure 18). Whole, human blood
is perfused though at a shear rate of 3,500 s−1, or just above 2,000s−1, the lower
threshold level of shear induced platelet activation.[6]
Figure 18: Whole blood is perfused from a syringe pump, past a pressure transducer
and through a pyrex, collagen coated test section which is placed under a microscope.
A high resolution camera takes images in real time through the microscope.
The test section through which the blood flows was created and collagen coated
as previously described.[21] The original inner diameter of the tube is 1.5mm and
the severity of stenosis used during experimentation range from 78% to 92%. To
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attain the prescribed shear rate of 3,500s−1, flow rates were calculated using Poiseuille
assumptions.
4.0.15.2 Whole Human Blood
Whole, human blood was drawn at the Georgia Institute of Technology’s Health
Center from consented subjects according to IRB protocol H06190. Blood was drawn
directly into syringes containing 3.5 USP units/mL heparin (Sigma-Aldrich, St Louis,
MO). This amount of heparin was chosen based on previous porcine experiments
to prevent clotting during transport while still allowing thrombus formation during
experimentation.[21] All blood was used within 8 hours of harvestm. Most of the
experiments were conducted at the beginning of this 8 hour window, although no
apparent differences were measured during experimentation time. During the flow
experiments, excess blood was placed on an LS orbital mixer (Labnet, Woodbridge,
NJ) to prevent blood separation.
4.0.15.3 Experimental Design
All of the experiments were conducted in three steps as seen in Figure 19. In the first
step (Figure 19 A), up to 10mLs of untreated blood is perfused through a stenosis
until initial visible deposition is seen. This allows for platelets to initially adhere to
the surface. In the second step (Figure 19 B), up to 10mLs of blood treated with
an anti-thrombotic therapy is perfused through the same stenosis. For the final step
(Figure 19 C), up to 10mLs of untreated blood is perfused through the same stenosis.
This ensures that the blood is thrombogenic. Experiments in which RPA did not
occur in the second or third syringe were discarded as the effect of the treatment on
RPA could not be determined on blood in which RPA did not occur.
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Figure 19: Experiments were completed in a three step approach. Initially, up to
10mLs of untreated blood was perfused through a collagen coated test section until
visible initial thrombus deposition occurred (A). This was followed by perfusing up to
10mLs of blood treated with an anti-thrombotic agent through the same test section
(B). Lastly up to 10mLs of untreated blood was perfused through the test section
(C). Times shown are relative to the initiation of flow for that particular step.
4.0.15.4 Dosing
All pharmaceuticals and chemicals were reconstituted with a difference between the
volume of chemical/drug used and saline to yield 1mL of total solution added to
the 10mL syringe of blood. All chemicals were mixed according to manufacturer’s
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specifications.
Abciximab and Eptifibatide A 10x dose was calculated using the original recom-
mended dose of 0.25mg/kg and 0.36mg/kg for abciximab and eptifibatide re-
spectively. Assuming an average body weight of 70kg and a total blood volume
of 5L, the final dose was determined to be 0.35mg of abciximab and 0.504mg
of eptifibatide per 10mLs of whole blood used. The high dosage used was to
ensure receptor blocking.
ASA A 10x dose was calculated for ASA (Sigma-Aldrich, St. Louis, MO) - based
on a low-daily dose of 100mg and 5L of total blood volume.[16] This resulted
in a mixture of 2mg of ASA and saline (1mL total added volume) which were
added to 10mL of whole blood. The high dosage used was to ensure receptor
blocking.
PGE1 and 2-MeSAMPS Experimental doses for PGE1 (Sigma-Aldrich, St. Louis,
MO) and 2-MeSAMPs, a clopidogrel stand-in, (as it does not need to be metab-
olized to block P2Y12, Sigma-Aldrich, St. Louis, MO) were 10µM and 50µM as
previously described by Ruggeri et al and Andre et al respectively for blocking
activation.[2, 18, 22]
4.0.15.5 Images
The test section was photographed through a 2x microscope objective using a high
resolution digital CCD camera (Pixelfly, Keleim, Germany) connected directly to the
Zeiss Stemi 2000-C (Zeiss, Jena, Germany) stereo microscope. The camera had a
corresponding lens which had a 0.5x magnification, yielding a final magnification of
1x and a resolution of approximately 7µm/pixel. Images were taken sequentially
in real time (1 frame/sec) and post processed using CamWare (Cooke Corporation,
Romulus, MI) and Photoshop (Adobe, San Jose, CA).
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4.0.15.6 Embolus
Embolus was defined as a visible mass seen entering the stenosis which caused an
instantaneous increase in pressure. Two types of embolus seen during experimentation
are shown below in Figure 20. Adherent embolus (Figure 20 A) was seen as a visible
mass entering the stenosis which adhered to the stenotic test section and persisted
for minutes during experimentation (Figure 20 A, 1, 2). In one case, the embolus
changed position at the end of experimentation due to fluid forces (Figure 20 A, 3,
4). Adherent embolus volumes were not included in the thicknesses or deposition rates
reported, with areas containing embolus being excluded from measurement as platelet
deposition rates were equivalent prior to and following an embolic event. Transient
embolus (Figure 20 B) was also not included during experimentation. Transient
embolus was defined as the instantaneous, non adherent movement of a visible mass
seen entering the stenosis and exiting within seconds (Figure 20 B, 1-4). Occasionally,
the transient embolus would remove previously deposited thrombus. While decreases
in thrombus thickness and volume were seen due to the mass pushing out adherent
thrombus, the presence of embolus was deleted from the analysis due to rates prior
to and after embolitic events being comparable.
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Figure 20: (A) Adherent embolus is debris which enters the test section quickly
(A1,A2), but remains for minutes during experimentation (A3). In the event shown,
the embolus shifted near the end of experimentation (A4). (B) Transient embolus
also occurs during experimentation and is seen as rapidly transiting debris (B1-B4),
which exits the tube within seconds.
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4.0.15.7 Additional Thickness/Volume/Accumulation Rates
Thickness of platelet accumulation was measured as the difference between the steno-
sis inner diameter and the inner diameter of the thrombus protruding into the lumen.
The increase in thickness is determined by subtracting the initial thickness at the
beginning of each new 10mLs perfused. The maximum thickness reported was taken
at a single location in the stenosis at the time when accumulation was greatest. Av-
erage thickness was calculated for each set of experiments by averaging the maximum
thickness values over each position a distance 0.19 − 0.24mm apart. The thickness
reported for each stenosis in each set of experiments is from the time of maximum
thickness during experimentation.








where DO was the diameter of the inside of the glass stenosis and the inner di-
ameter, DI , was the diameter created by measuring the top of the thrombus growing
from the bottom of the tube and the bottom of the thrombus growing from the top
of the tube. By summing the cylinders, the volume was then integrated along the
length of the thrombus, L, which was divided into equal segments which ranged in
length for each set of images from 0.19 − 0.24mm.
Surface area used was the total surface area that thrombus deposited on during




Where DO is the inner diameter of the stenosis for each segment on which thrombus
deposited on during experimentation.






Volume/Time is a regression of the volume over at least three consecutive time
points, with the three time points encompassing a minimum of 2 minutes of the volume
growth of thrombus formation. For all experiments, the maximum accumulation rate
was calculated using at least three points. If the maximum did not exceed RPA, or
an accumulation rate ≥ 1.6 µm3µm−2min−1, a regression of the volumetric growth
over the total time of experimentation was calculated.[21]
4.0.15.8 Statistics
Experiments were analyzed using a student’s t-test where statistical significance is
defined as p<0.05.
4.0.16 Results
Results are presented for the general activation inhibitors (PGE1, 2-MeSAMPS, and
ASA), followed by αIIbβ3 specific inhibitors (abciximab and eptifibatide).
4.0.16.1 RPA Requires Activation Mediated by PGE1 Pathway
We explored the effects of blocking activation on RPA under high shear conditions.
PGE1
The incremental thrombus thickness beyond the initial deposition is shown in
Figure 21. The added thickness in each individual stenosis is shown for blood treated
with PGE1 (Figure 21 A) as well as untreated blood which was subsequently perfused
(Figure 21 B). This is followed by the thickness averaged by position (Figure 21, C and
D) and is also shown with standard deviations (Figure 21, E and F). In general, little
thrombus thickness was observed in the PGE1 group. There was significantly less
added maximal thickness in blood treated with PGE1 (11 ± 12 µm, n=5, Figure 21
C) than untreated blood (138 ± 84 µm n=5, p<0.05, Figure 21 D).
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Figure 21: Measured thicknesses following the perfusion of blood treated with A)
PGE1 and the subsequent perfusion of B)untreated blood. There was a significant
increase in maximum thicknesses (∗, p<0.05) for D)untreated blood following the per-
fusion of treated blood when compared to C)blood treated with PGE1. The averages
with standard deviations for E)treated blood and F)untreated blood are also shown.
Individual volume growths are shown over time for blood treated with PGE1
(Figure 22 A). For comparison, the amount of thrombus volume accumulation over
time in the same test section with normal blood (control) immediately after is shown
(Figure 22 B). The additional volume added during experimentation was 1.0 ± 7.0
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∗10−6cm3 (1.0 ± 7.0 ∗106µm3)in PGE1 treated blood (n=5), which was an order of
magnitude lower than untreated blood 42 ± 52 ∗10−6cm3 (n=5).
Figure 22: Calculated volumes are shown for blood treated with PGE1 (A) and
subsequently perfused untreated blood (B)
PGE1 added to whole blood completely inhibited RPA, with RPA occurring in
0/5 samples of treated blood (p<0.05), whereas RPA occurred in the untreated
71
blood (n=5/5). Average deposition rates for the PGE1 treated blood were -0.1 ±
0.3 µm3µm−2min−1 (n=5) and were significantly lower than the RPA rates for the
untreated blood (3.2 ± 1.7 µm3µm−2min−1, n=5, p<0.05).
2-MeSAMPS 2-MeSAMPS blocks the P2Y12 pathway of platelet activation and
does not need to be metabolized like clopidogrel.
Figure 23 A depicts the 5 experiments using 2-MeSAMPS and is followed by un-
treated blood perfused immediately after (Figure 23 B). The average added thickness
is shown in Figure 23 C for 2-MeSAMPS treated blood (n=5) and is followed by
untreated blood which was perfused immediately following (n=4) and is also shown
with standard deviations (Figure 23, E and F). The maximum thickness deposited
in 2-MeSAMPS treated blood is significantly smaller (27 ± 21 µm, n=5) than the
subsequent perfusion of normal blood (138 ± 55 µm, p<0.05, n=4, Figure 23 D).
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Figure 23: Measured thicknesses following the perfusion of blood treated with A)
2-MeSAMPS (n=5) and the subsequent perfusion of B)untreated blood (n=4). There
was a significant increase in the maximum thicknesses (∗, p<0.05) for D)untreated
blood (n=4) following the perfusion of treated blood when compared to C)blood
treated with 2-MeSAMPS (n=5). The averages with standard deviations for
E)treated blood and F)untreated blood are also shown.
Treatment of whole blood with 2-MeSAMPS reduced the amount of thrombus
formation over time (Figure 24 A) as compared to the control with normal blood
(Figure 24 B). The additional volume added during experimentation was 4.8 ± 4.5
∗10−6cm3 in 2-MeSAMPS treated blood (n=5), which was lower than untreated blood
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59 ± 44 ∗10−6cm3 (n=4).
Figure 24: Calculated volumes are shown for blood treated with 2-MeSAMPS (A)
and subsequently perfused untreated blood (B). Volumes are lower for treated blood.
In blood with 2-MeSAMPS, the average accumulation rates for samples which
did not go to RPA were 0.002 ± .22 µm3µm−2min−1 (n=4) and minimal volume
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deposition can be seen during experimentation (Figure 25). The platelet deposition
rate in the treated syringe which exceeded RPA was 3.7 µm3µm−2min−1 (n=1, 85%
stenosis). Combined, the rates with 2-MeSAMPS were significantly slower than the
RPA rates of the untreated syringe (4.1 ± 1.7 µm3µm−2min−1, n=4, p<0.05). One of
the four samples of 2-MeSAMPS treated blood in which RPA was prevented was dosed
with 30nM of epinephrine (a high physiologic amount) to increase thrombogenicity
in the blood overall.[19, 8]
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Figure 25: The average measured A)thickness and calculated B)volume of blood
which was treated with 2-MeSAMPS (n=4).
RPA was present in 1/5 (20%) of samples with 2-MeSAMPS, although it was a
significant inhibitor of RPA, with RPA occurring in only 1/5 of treated blood samples
and in 4/4 of the following untreated samples (p<0.05). Thus, there was an example
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of blood treated with a 10x dose of this P2Y12 inhibitor which did not show adequate
anti-platelet activity under high shear in our assay.
ASA
Acetylsalicylic acid is the active ingredient in aspirin. The maximum thicknesses
are shown in Figure 26 A for ASA treated blood and in Figure 26 B for the untreated
blood immediately following. Their averages with standard deviations can be seen
in Figure 26, E and F. The maximum thickness for the ASA treated blood (66 ±
42 µm, n=7, Figure 26 C) was significantly less than the maximum thickness in the
untreated blood (217 ± 158 µm, n=3, p<0.05, Figure 26 D).
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Figure 26: Measured thicknesses following the perfusion of blood treated with A)
ASA (n=7) and the subsequent perfusion of B)untreated blood (n=3). There was a
significant increase in maximum thickness(∗, p<0.05) for D)untreated blood following
the perfusion of ASA treated blood (n=3) and C)blood treated with ASA (n=7). The
averages with standard deviations for E)treated blood and F)untreated blood are also
shown.
The amount of thrombus volume growth over time is shown in Figure 27 A for
ASA, as compared to the control growth seen in Figure 27 B. The additional volume
added during experimentation was 26 ± 35 ∗10−6cm3 in ASA treated blood (n=7)
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and 62 ± 86 ∗10−6cm3 (n=3) in untreated blood.
Figure 27: Calculated volumes are shown for blood treated with ASA (A) and sub-
sequently perfused untreated blood (B).
RPA was present in 4/7 (57%) of ASA treated samples. In the samples in
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which RPA was prevented average deposition rates in ASA treated blood were -
0.01 ± 0.3 µm3µm−2min−1 (n=3). RPA rates in the untreated blood were 3.7 ± 1.1
µm3µm−2min−1 (n=3). ASA treated blood which went to RPA had rates of 2.8 ±
0.8 µm3µm−2min−1 (n=4).
Thus, there were several examples of blood treated with ASA that did not show
adequate anti-platelet activity under high shear in our assay, indicating that that ASA
treated blood was not as effective in preventing RPA and exhibited more thrombus
volume deposition under high shear.
4.0.16.2 αIIbβ3 Blocking Agents
Abciximab
Abciximab (Reopro R©) is a Fab fragment of a monoclonal antibody against αIIbβ3.
Following visible initial adhesion, added thickness was measured for the following
syringes containing blood treated with abciximab and untreated blood respectively
(Figure 28, A and B). There was a significant increase in the maximal thicknesses in
untreated blood (154 ± 30 µm, n=6, Figure 28 D) versus the maximal thickness in
blood treated with abciximab (28 ± 19 µm, n=6, p<0.05, Figure 28 C).
80
Figure 28: Measured thicknesses following the perfusion of blood treated with A) ab-
ciximab and the subsequent perfusion of B) untreated blood. There was a significant
increase in thickness (∗, p<0.05) in the average maximal thickness for D)untreated
blood following the perfusion of treated blood when compared to C) blood treated
with abciximab. The averages with standard deviations for E) treated blood and F)
untreated blood are also shown.
Treatment of blood with abciximab prevented the formation of large amounts of
thrombus volume as shown in Figure 29 A (n=6). For comparison, the volume of
platelets deposited over time is shown for the control blood in Figure 29 B (n=6).
There was a significant increase in the added volume during experimentation in the
untreated blood, which averaged 32 ± 22 ∗10−6cm3 (p<0.05, n=6), than the blood
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treated with abciximab which averaged 1.4 ± 7.0 ∗10−6cm3 (n=6).
Figure 29: Volume deposition over time was calculated for blood treated with ab-
ciximab (A) and untreated blood which was subsequently perfused (B). The average
added volume deposited in the untreated blood (32 ± 22 ∗10−6cm3, n=6) was sig-
nificantly greater than the average maximal added volume in the blood treated with
abciximab (1.4 ± 7.0 ∗10−6cm3, n=6, p<0.05).
Rapid platelet accumulation did not occur in any blood sample treated with abcix-
imab (n=0/6), with a significantly higher occurrence of RPA occurring in untreated
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blood (p<0.05, n=6/6). As RPA did not occur in blood treated with abciximab,
average deposition rates of the treated blood were compared with RPA rates in the
untreated blood resulting in a significant increase in the final thrombus volume de-
position in untreated blood (6.2 ± 2.4 ± 0.8 µm3µm−2min−1, p<0.05, n=6) versus
treated blood (0.1 ± 0.1 ± 0.8 µm3µm−2min−1, n=6).
Eptifibatide
Eptifibatide (Integrilin R©) functions as a competitive small molecule against the
binding site.
Added maximal thickness measurements for all blood treated with eptifibatide
(Figure 30 A) and the subsequently perfused untreated blood (Figure 30 B) are shown
below. An eptifibatide treated, 84% stenosis shows a marked increase in thickness
deposition compared to the other treated syringes (Figure 30 A), causing the average
added maximum thickness for the treated blood (167 ± 19 µm, n=5, Figure 30 C) to
exceed those of the untreated samples (121 ± 38 µm, n=4, Figure 30 D).
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Figure 30: Measured thicknesses following the perfusion of blood treated with A)
eptifibatide and the subsequent perfusion of B)untreated blood. The average maxi-
mal thickness was also represented for blood treated with eptifibatide (n=5, C) and
untreated blood perfused following (n=4, D). The averages with standard deviations
for E)treated blood and F)untreated blood are also shown.
Excluding this one sample, the effect of effective eptifibatide treatment can be
seen below (n=4, Figure 31) for average maximum thrombus deposition (Figure 31
A) and volume growth (Figure 31 B). Overall, there is a net negative volume growth
in eptifibatide-responsive blood treated during experimentation.
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Figure 31: The average measured A)thickness and calculated B)volume of blood
which was treated with eptifibatide in which RPA was prevented (n=4).
In 4/5 (80%) experiments, Eptifibatide showed no thrombosis volume growth
following initial adhesion (Figure 32 A). The average added volume in eptifibatide
treated blood was -10 ± 12 ∗10−6cm3 (n=5, Figure 32 A). The average added volume
in the subsequently perfused untreated blood was 16 ± 16 ∗10−6cm3 (n=4, Figure 32
B). There is a marked increase in additional thrombus volume (Figure 32 A) in the
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treated stenosis in which RPA occurred versus the other treated samples in which
RPA was prevented (Figure 32 A).
Figure 32: The added maximal thrombus volume deposited was calculated for both
blood treated with eptifibatide (A) and untreated blood (B).
Significant prevention of RPA occurred in blood treated with eptifibatide (n=4/5,
p<0.05), with RPA occurring in an 84% stenosis (n=1/5).
RPA rates averaged 5.9 ± 4.3 µm3µm−2min−1 for untreated blood (n=4) and
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average deposition rates of eptifibatide treated blood in which RPA did not occur
averaged -0.3 ± 0.1 µm3µm−2min−1 (n=4). In the sample of treated blood which
achieved RPA, the RPA rate was 12.5 µm3µm−2min−1 (n=1, 84% stenosis).
Overall, abciximab and PGE1 were the only therapies which completely prevented
RPA and significantly inhibited maximal thickness deposition. Eptifibatide and 2-
MeSAMPS were also significant inhibitors of RPA, but not of thickness deposition.
ASA was the least successful at preventing RPA.
4.0.16.3 Response to therapies is patient/time specific
Patient Specific Results
It is possible that blood drawn at different times from the same individual may
react differently over time. We compared the results of treatment for two subjects to
evaluate variations within an individual. The responses listed in Table 3 show that
responses to treatment can depend on the person or change over time. For subject 1,
PGE1 and abciximab prevented RPA, while 2-MeSAMPS, ASA, and eptifibatide did
not. In the case of subject 2, all pharmaceuticals worked. However, a repeat of ASA
in Subject 2 was performed one month later that showed less susceptibility to ASA
and the presence of RPA. This time variation in the blood of Subject 2 suggests that
testing of a patient for high shear thrombosis may be needed periodically.
Table 3: The ability of each investigatory drug to inhibit RPA is shown above for
two subjects. A (+) indicates RPA prevention. Otherwise, (– ) is shown.
Abciximab Eptifibatide 2-MeSAMPS PGE1 ASA
Subject 1 + – – + –
Subject 2 + + + + + and –
87
4.0.17 Discussion
We have evaluated the efficacy of five anti-platelet agents to block thrombosis in
a collagen coated tubular stenosis test section where shear stress exceeds 3500s−1.
Blockade of high shear thrombus formation by PGE1 was complete, whereas ASA
was not uniformly effective. A Plavix R© analog called 2-MeSAMPS generally worked
with most blood with a failure in the blood from only one subject. Blockade of αIIbβ3
by abciximab, completely blocked thrombus under high shear, whereas eptifibatide
had a notable failure. The endpoints of thrombus volume, thickness and growth rate
yielded similar results in our assay.
Clinically, it is common to evaluate an entire cohort for treatment and efficacy.
Thus, we can combine all treatments together and compare these results to the con-
trol, normal blood. Treatment by any means had a net overall reduction in thrombosis
that was statistically significant. RPA was prevented in 22/28 (79%, p<0.05) If RPA
did not occur, an average deposition rate during the duration of experimentation was
used. Treatment significantly slowed accumulation rates to 0.9 ± 2.6 µm3µm−2min−1
(n=28) Untreated blood had RPA rates of 4.7 ± 2.6 µm3µm−2min−1 (n=22, p<0.05).
This indicates that treatment is globally better than nothing, but serving as a re-
minder that patient-specific treatment would be a more effective course of action.
Activation blockade by the different agents work by different mechanisms and path-
ways. Blockade of P2Y12 receptors and treatment with ASA were not effective against
RPA in all blood samples, consistent with clinical findings.[1, 13, 15] Similarly, we
found that certain blood may be resistant to eptifibatide while being responsive to
abciximab. In comparison, the clinical data on the differences between these two
therapies are not conclusive.[5]
The blockade of large scale thrombosis by activation in our flow system may ap-
pear to contradict findings by Ruggeri et al for very high shear conditions.[22] There
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are differences which may be important between these assays. While Ruggeri uti-
lized platelet-surface deposition measurements, our experiment evaluated endpoints
of thickness, volume and accumulation rates which would be due to platelet-platelet
accumulation. There was not always a correlation between significance found for
volume and thickness, potentially due to any measurement errors being squared.
Further, as the therapies tested may slow accumulation without preventing it, the
maximum thickness deposited may be the most clinically relevant endpoint mea-
sured. The platelet-platelet accumulation may require activation and stabilization of
mural platelets for very high shear attachment by released vWF.[26] Our thrombosis
persisted for ten minutes after initial adhesion, requiring stabilization by activated
αIIbβ3 that would persist long after the short GPIb binding observed in the Ruggeri
very high shear study.[22] Thirdly, our initial shear rate was 3,500 s−1 versus the
10,000s−1 used by Ruggeri et al. The lower initial shear may require more activation
than very high shear conditions.
The susceptibility of blood to antiplatelet agents appears to be patient specific.
We evaluated only one 10x dose or described in vitro doses for blocking of each of
these drugs. We did not perform a dose-response curve. The testing of blood with
a variety of pharmaceutical agents may be important in establishing patient-specific
anti-platelet therapy instead of giving all patients the same anti-platelet drug and
dosage.
Our human, single pass, syringe pump experiment has several limitations. The
first is that it requires 30mLs of blood for each trial. As only 500mLs can be taken
from a patient within 6 weeks, this would allow for approximately 16 different therapy
regimens to be tested. Depending on the patient’s platelet response, 16 permutations
of therapies could potentially prove limiting. Further, there is no physiologic pulsatil-
ity in the system, which could be added in future testing. The addition of pulsatility
has unclear implications on deposition rates.[23, 28] Another limitation of the system
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is the use of heparin which may impair platelet deposition rates.[14] While it does
not prevent RPA, it may decrease the actual rate of accumulation.
4.0.18 Conclusion
An in vitro hemodynamic system of high shear thrombosis is adapted to test patient-
specific responses to a variety of anti-platelet therapies in an effort to develop more
effective patient-specific treatments.
PGE1, 2-MeSAMPS, ASA, abciximab and eptifibatide were evaluated for the pre-
vention of RPA in a collagen coated stenosis at shear rates >3,500s−1. The effec-
tiveness of each pharmaceutical in reducing the amount and rate of thrombosis was
different. Blockade of activation, mediated by PGE1 was most effective in our high
shear system while 2-MeSAMPS and ASA were less effective at preventing throm-
bus growth and RPA. αIIbβ3 blockade via abciximab prevented RPA and permanent
thrombus accumulation in all tested blood whereas eptifibatide was less effective.
Further, we note in one patient that ASA was effective one month, but not the next
month. The time variation suggests that patients may need to be tested periodically
to accommodate physiological changes in platelet behavior.
Overall, inhibition of αIIbβ3 using abciximab and blocking platelet activation using
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CHAPTER V
THROMBOSIS IS INCREASED BY EXCESS AMOUNTS
OF VON WILLEBRAND FACTOR AT VERY HIGH
SHEAR RATES
5.0.20 Introduction
High shear occlusive thrombosis occurs in two stages. Initial adhesion constitutes
the attachment of platelets on the damaged subendothelium and is followed by the
subsequent accumulation of platelets onto platelets previously adhered to the surface.
If the subsequent platelet-to-platelet thrombosis is massive (millions of platelets),
then we refer to this large thrombus growth as Rapid Platelet Accumulation (RPA).[5]
RPA occurs when volume accumulation rates exceed 1.6 µm3µm−2min−1.[5] Following
platelet activation, Glycoprotein IIb/IIIa (αIIbβ3) can contribute to the formation of
mural thrombus under high shear conditions.[6, 7, 14]
vWF is a multimeric protein that allows for the attachment of platelets to the
vessel wall following injury as well as platelet-to-platelet interaction necessary for
occlusion.[7, 10] vWF is present after platelet activation on the surface of thrombus
formation with a 50x higher concentration than in plasma.[2, 15] vWF is shear depen-
dent, elongating at shear rates greater than 6,000s−1.[9] In a patient study of 9,758
men and women between the ages of 50-59, there was a three-fold increase in ischemic
heart disease in subjects who had high vWF levels in the top quartile when compared
to those in the bottom quartile.[3, 4] This increase in risk for ischemic heart disease
coincided with approximately a 2x increase in vWF levels on average.[4]
Conversely, patients who are suffering from von Willebrand Disease (vWD) and
have a deficiency of vWF, tend to have longer bleeding times.[8] Bleeding times can
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be (partially) corrected by the addition of purified vWF in patients with VWD,
suggesting that thrombus deposition may be influenced by vWF concentration.[11]
It is the goal of this study to determine if excessive amounts of vWF in whole,
human blood will increase thrombus deposition under high (3,500s−1) and very high
shear stress (10,000s−1). Our hypothesis is that addition of vWF to whole blood or
the surface of thrombus formation will increase thrombus thickness and increase RPA
rates.
5.0.21 Experimental Design and Methods
5.0.21.1 Syringe Pump Apparatus
A single pass, syringe pump fed, in-vitro system was created in which thrombus
formation could be viewed under a microscope (Figure 33). Whole, human blood is
perfused though at either a shear rate of 3,500 s−1 (just above 2,000s−1, the lower level
of shear induced platelet activation) or 10,000 s−1, above the level of vWF elongation.
[1, 9]
Figure 33: Whole blood is perfused from a syringe pump, past a pressure transducer
and through a pyrex, collagen coated test section which is placed under a microscope.
A high resolution camera takes images in real time through the microscope.
The test section through which the blood flows was created and collagen coated
as previously described.[5] The original inner diameter of the tube is 1.5mm and the
severity of stenosis used during experimentation range from 80% to 93%. Flow rate
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for each experiment was prescribed using Poiseuille assumptions.
5.0.21.2 Whole Human Blood
Whole, human blood was drawn at the Georgia Institute of Technology’s Health
Center from consented subjects according to IRB protocol H06190. Blood was drawn
directly into syringes containing 3.5 USP units/mL heparin (Sigma-Aldrich, St Louis,
MO). This amount of heparin was chosen based on previous porcine experiments
to prevent clotting during transport while still allowing thrombus formation during
experimentation.[5] All blood was used within 8 hours of harvest. During the flow
experiments, excess blood was placed on an LS orbital mixer (Labnet, Woodbridge,
NJ) to prevent blood separation.
5.0.21.3 Experimental Design
All experiments were conducted in multiple steps utilizing the same stenosis. In the
first step, up to 10mLs of untreated blood was perfused through a stenosis until
visible initial deposition is observed. This allows for platelets to initially adhere to
the surface. The second step is determined by the type of experiment run (see below).
vWf Enriched Blood
For the second step in vWF saturated blood, 35IU of vWF from Humate-P R© (CSL
Behring, LLC, King of Prussia, PA) and saline (for a total added volume of 1mL) was
added to 10mLs of whole blood and mixed using a rotating motion. Humate-P R© is a
homogenized, purified plasma vWF product which contains factor VIII.[16] 1 IU is the
activity of vWF in 1mL of healthy plasma.[11] Through experimentation (not shown
here), it was determined that there were approximately 3.5mLs of plasma in 10mLs
of whole blood. A 35IU dose of vWF would therefore increase the concentration of
vWF to 8.6x. Blood was used immediately for experimentation.
vWF Coated Surface
For the second step of a vWF coated surface, 35 IU of vWF from Humate-P R©
98
(CSL Behring, LLC, King of Prussia, PA) were incubated in the stenosis following
initial visible adhesion for 1 hour at room temperature, similar to methods previously
described by Sixma.[11] Up to 10mLs of untreated, whole blood was then perfused
over the surface.
5.0.21.4 Images
The test section was photographed through a 2x microscope objective using a high
resolution digital CCD camera (Pixelfly, Keleim, Germany) connected directly to the
Zeiss Stemi 2000-C (Zeiss, Jena, Germany) stereo microscope. The camera had a
corresponding lens which had a 0.5x magnification, yielding a final magnification of
1x. Images were taken sequentially in real time and post processed using CamWare
(Cooke Corporation, Romulus, MI) and Photoshop (Adobe, San Jose, CA).
5.0.21.5 Additional Thickness/Volume/Accumulation Rates
Thickness of platelet accumulation was measured as the difference between the steno-
sis inner diameter and the inner diameter of the thrombus protruding into the lumen.
The increase in thickness is determined by subtracting the initial thickness at the
beginning of each new 10mLs perfused. The maximum thickness reported was taken
at a single location in the stenosis at the time when accumulation was greatest. Av-
erage thickness was calculated for each set of experiments by averaging the maximum
thickness values over each position a distance 0.19 − 0.24mm apart. The thickness
reported for each stenosis in each set of experiments is from the time of maximum
thickness during experimentation.








where DO was the diameter of the inside of the glass stenosis and the inner di-
ameter, DI , was the diameter created by measuring the top of the thrombus growing
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from the bottom of the tube and the bottom of the thrombus growing from the top
of the tube. By summing the cylinders, the volume was then integrated along the
length of the thrombus, L, which was divided into equal segments which ranged in
length for each set of images from 0.19 − 0.24mm.
Surface area used was the total surface area that thrombus deposited on during




Where DO is the inner diameter of the stenosis for each segment on which thrombus
deposited on during experimentation.





Volume/Time is a regression of the volume over at least three consecutive time
points, with the three time points encompassing a minimum of 2 minutes of the volume
growth of thrombus formation. For all experiments, the maximum accumulation rate
was calculated using at least three points. If the maximum did not exceed RPA, or
an accumulation rate ≥ 1.6 µm3µm−2min−1, experiments were not included in this
study.
5.0.21.6 Embolus
Embolus was defined as a rapid increase in pressure and a sudden presence in the tube.
Embolus intrusion into the stenosis was excluded from thrombus volume deposition
measurements regardless of whether it was a transient or permanent event.
5.0.21.7 Statistics




We compared thrombus formation with i) normal whole blood, ii) whole blood with
added Humate-P, and iii) whole blood over surfaces of Humate-P that was additionally
deposited on the surface. As we were focusing on Phase II of massive thrombosis,
10 ml of normal blood was perfused through each test section prior to the study
conditions to lay down an initial layer of platelets on the raw collagen surface. Whole
blood was perfused at two shear rates, 3,500s−1 (high shear) and 10,000s−1 (very high
shear). The endpoints for thrombus formation were thrombus thickness, thrombus
volume, and rate of accumulation.
The thrombus thickness in the 6 different test sections with vWF enriched blood is
shown in Figure 34 A for a shear rate of 3,500 s−1. The average thickness for these test
sections is shown in Figure 34 B. The additional 1mL volume of vWF solution may
affect the amount of thrombosis. As a control, Figure 34 C illustrates the thickness of
4 experiments where an additional 1 ml of saline was added to the blood. Note that
the individual and average thrombus thicknesses were the same with the added saline.
There were no significant differences between the average thicknesses for samples with
vWF added to blood and the control with saline (Figure 34, B and D).
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Figure 34: Thicknesses for each sample were measured in the stenosis for vWF
enriched blood (A). Average thicknesses was also calculated for vWF enriched blood
samples (B). Thickness was also measured for control blood in which saline was added
(C). Average thickness for the control was also calculated (D). All started at an initial
shear rate of 3,500s−1.
The second study condition was to deposit excessive amounts of vWF directly on
the thrombus surface. Figure 35 A illustrates the thrombus thickness results with
excess vWF on the surface. Figure 35 C shows the normal control with saline on the
surface. No significant differences were measured between the average thicknesses at
the apex between the vWF surface (Figure 35 B) and the control with saline (Fig-
ure 35 D). Likewise, no differences were seen with the average thickness by position
(Figure 35 B and Figure 35 D).
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Figure 35: Thicknesses for each sample were measured in the stenosis with a vWF
enriched surface (A). Average thicknesses were calculated for vWF enriched surface
samples (B). Thickness was also measured for the control in which saline was added
to the surface (C). The average for the control is also shown (D). All flow experiments
started at an initial shear rate of 3,500s−1.
5.0.22.1 Addition of vWF to blood increased thickness at the apex over adding
vWF to the surface at 3,500s−1.
A significantly greater maximum thickness was measured for samples in which vWF
was added directly to the blood (n=6) than those in which vWF was added directly
to the surface (n=3, p<0.05, Figure 36).
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Figure 36: Thrombosis thickness formed at high shear rates (3,500s−1), with vWF
enriched Blood (above) and vWF enriched surfaces (Below) There is a significantly
greater average thickness in vWF enriched blood (n=6) versus a vWF enriched sur-
faces (n=3, p<0.05).
Thrombus volume was also calculated for the treatments and their controls at
3,500s−1 (Figure 37). Maximum volume was 35 ± 26 ∗10−6cm3 (n=6, Figure 37 A)
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for samples in which vWF was added directly to the blood and 22 ± 3.3 ∗10−6cm3
(n=4, Figure 37 B) for the controls containing saline. In the samples with the coated
surface, the maximum volume was 10 ± 0.3 ∗10−6cm3 (n=3) for the vWF coated
surface (Figure 37 C) and 12 ± 4.6 ∗10−6cm3 (n=3) for the saline coated control
(Figure 37 D).
Figure 37: Volume growth of thrombus over time at 3,500s−1 for individual experi-
ments. (A) Blood enriched with vWF, (B) saline enriched blood, (C) Surface enriched
with vWF, (D) and the saline surface controls.
5.0.22.2 Increasing the vWF concentration in blood at 10,000s−1 increases the
maximum thickness deposited
Following vWF addition into whole blood, thickness of thrombus in the stenosis was
measured at an initial shear rate of 10,000s−1 (Figure 38 A). Thickness was measured
for the control to which saline was added rather than vWF (Figure 38 C). Blood
which had been enriched with vWF had a significantly greater average thickness (n=5,
Figure 38 B) than its control in which saline was added to blood (n=3, Figure 38 D,
p<0.05).
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Figure 38: Thrombus thicknesses for vWF enriched blood at an initial shear rate
of 10,000s−1. (A) Individual thickness. (B) Average thickness. (C) Thickness for
control blood in which saline was added. (D) Average thickness for saline control.
The average thickness with vWF enriched blood (n=5) was greater than the saline
control (n=3, p<0.05).
Thickness of thrombus formation at very high shear was measured for the surface
coating experiments in which vWF was incubated in the stenosis (Figure 38 A) and its
saline control (Figure 39 C). No significant differences were found between thicknesses
at the apex between the vWF surface (Figure 39 B) and the control (Figure 39 D).
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Figure 39: Thrombosis thicknesses at a shear rate of 10,000s−1: (A) vWF enriched
surface. (B) Average thickness for the treated samples . (C) Thickness for the control
in which saline was added to the surface. (D) Average thickness for the control.
No significant differences were found between average thicknesses for vWF en-
riched blood at shear rates of 3,500s−1 versus vWF enriched blood at 10,000s−1
(p=0.971).
The average thickness for vWF treated blood and the vWF treated surface were
compared (Figure 40), showing no significant difference between the two at shear
rates of 10,000s−1 (p>0.05). Although, when compared to the vWF treated surface
at 3,500s−1 (n=3), there was suggestive evidence indicating that that the higher shear
rate of 10,000s−1 yielded a thicker deposition (n=4, p=0.159).
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Figure 40: Thrombus average thickness at very high shear rates (10,000s−1) from
vWF enriched blood (above) and vWF enriched surface (below). There was no signif-
icant difference in average thickness on a surface coated with vWF versus the control
surface coated with saline (p=0.525).
Maximum volume was also calculated for the treatments and their controls at
3,500s−1 (Figure 41). Maximum volume was 25 ± 20 ∗10−6cm3 (n=5, Figure 41 A)
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for samples in which vWF was added directly to the blood and 16 ± 11 ∗10−6cm3
(n=3, Figure 41 B) in the controls with saline in the blood. In the samples with
the coated surface, the maximum volume was 30 ± 40 ∗10−6cm3 (n=4) for the vWF
coated surface (Figure 41 C) and 10 ± 3.9 ∗10−6cm3 (n=3) for the saline coated
control (Figure 41 D).
Figure 41: Volume over time is shown for vWF enriched blood (A), saline enriched
blood (B), vWF enriched surface (C) and the saline enriched surface (D) at 10,000s−1.
5.0.22.3 Increasing the vWF concentration in blood at 10,000s−1 may increase
the max thrombus/surface area coverage.
A maximum volume of thrombus over the entire stenosis at any point in time was
obtained from the volume plots. The maximum volume per surface area was calcu-
lated for all of the treatments and their controls (Table 4). The maximum volume
of thrombus per surface area at 10,000s−1 for blood enhanced vWF was 3.16 ± 1.50
cm (n=5). The maximum volume of thrombus per surface area at 10,000s−1 for the
saline control was 1.44 ± 0.40 cm (n=3). This maximum was two times larger, but
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failed to reach statistical significance (p=0.073).
Table 4: The maximum volumes are shown in this table for all experiments and
saline controls. The p values for the vWF enhanced blood just missed statistical
significance.
vWF Volume/SA Control Vol/SA
(∗10−3cm) (∗10−3cm)
Blood 3,500s−1 1.95 ± 0.70 0.26 ± 0.66
Surface 3,500s−1 1.33 ± 0.72 1.41 ± 0.39
Blood 10,000s−1 3.16 ± 1.50 1.44 ± 0.40
Surface 10,000s−1 2.19 ± 1.90 1.57 ± 0.71
Thrombus thickness increases may stem from an increase in the rate of accumu-
lation. The calculated rates of accumulation were high (RPA) in every case, shown
in Table 5. At very high shear rates, the vWF enriched blood exhibited a higher
average rate, but failed to reach statistical significance. There is suggestive evidence
that adding vWF to blood at 10,000s−1(n=5) may increase RPA more than adding
vWF to the surface at 10,000s−1 (n=4, p=0.153), vWF to the blood at 3,500s−1 (n=6,
p=0.122) and vWF to the blood at 3,500s−1 (n=3, p=0.107).
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Table 5: The RPA rates for all of the vWF experiments and their controls are shown
above.
vWF RPA Control RPA
( µm3µm−2min−1) ( µm3µm−2min−1)
Blood 3,500s−1 2.09 ± 0.36 3.61 ± 1.53
Surface 3,500s−1 1.89 ± 0.20 2.24 ± 0.79
Blood 10,000s−1 5.42 ± 3.80 2.94 ± 0.77
Surface 10,000s−1 2.35 ± 0.78 2.97 ± 0.53
In general, the experiments exhibited a large range of accumulation rates fom 1.6
to 10 µm3 µm−2 min−1. The RPA rates for all treatment types are shown below as
compared to human untreated blood at 3,500s−1 (n=21, Figure 42).
Figure 42: The RPA rates for all vWF experiments are shown above as compared
with previous experiments with untreated blood at 3,500s−1 (n=21). illustrating the
wide range of accumulation rates seen in individuals. Note that the entire range of
accumulation rates is much greater than the initial deposition rates that average 0.8
± 1.0 µm3 µm−2 min−1 (n=21)
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5.0.23 Discussion
Our experiments show that whole blood enriched with vWF at 8.6x concentrations
increases thrombus thickness deposition at very high shear stress. The vWF enriched
blood created larger thrombus thickness compared with vWF deposited on the sur-
face. While some experiments showed higher RPA rates with blood enriched vWF,
the group as a whole did not reach the level of statistical significance. The in vitro
increase in thrombus thickness from high concentrations of vWF at very high shear
rates agrees with the clinical observation that high concentrations in blood levels of
vWF are associated with a 3 fold increase in ischemic heart disease.[3]
It is possible that only suggestive evidence indicates that RPA is increased as
thrombus growth may be limited by the arrival of platelets at the wall and not vWF
once normal vWF concentration levels have been reached.[17] Studies done by Sixma
where a normal amount of vWF was added to vWD blood show that the addition
of vWF increased thrombus formation, although it did not bring it back to normal
levels.[11] Ruggeri notes that additional soluble vWF enhances platelet adhesion and
rolling at higher shear rates on a vWF surface consistent with pathologic conditions.[7]
Excessive vWF in blood has not been tested. Similarly, a 8.6x concentration may not
be a sufficient concentration to influence thrombus formation beyond its normal levels,
potentially requiring a 50x concentration for a measurable change.[2, 15] There may
be a threshold for vWF where, once normal levels are met, a significantly larger
(potentially 50x) local concentration is required to push platelet deposition beyond
their normal rate at very high shear rates. Alternaatively, vWF may not be the rate
limiting protein for RPA once normal concentrations of vWF are attained.
Mere incubation of vWF in the test section may not bind the vWF to the surface
(immobilization). The vWF added to the surface may have washed off with the first
few mLs of blood perfusion. The vWF may also not have elongated, due to being
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applied under static conditions, and retained its globular form during experimenta-
tion. This would limit vWF’s ability to bind due to domains being sterically covered
in the globular formation.[7, 10]
We did not correct our results for subject-related factors, such as patient habits
(e.g. smoking, NSAID use, etc) or test for diseases such as von Willebrand Disease
which would alter platelet accumulation. Further, there may be a large interpersonal
variation which was not accounted for in this study. Our in vitro blood perfusion
system has several limitations. The studies are run at room temperature and not
at 37oC, which may decrease platelet deposition rates.[12] The temperature may be
corrected for in the future by using a heating coil to surround the syringe during
perfusion. Further, we did not impose arterial pulsatility. The literature is unclear
about the effects of pulsatility on platelet deposition.[13, 18]
5.0.24 Conclusion
This study finds that an increase in concentration of vWF in the blood increases
thrombus thickness at pathologic shear rates (10,000s−1). Blood enhanced vWF also
increases thickness over surface vWF at 3500s−1. The increase in thrombus thick-
ness with higher concentrations of vWF may be important for patients with stenotic
atherosclerotic lesions with very high shear rates. Local concentrations of vWF from
the blood or from local release by platelets or damaged endothelial cells may trigger
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CHAPTER VI
DISCUSSION OF THESIS RESULTS AND FUTURE
STUDIES
This dissertation explored the formation of intravascular thrombosis in a stenosis with
high shear rates. Initially, thrombosis was created in vitro with a collagen-coated
stenosis perfused with whole porcine blood (Chapter 2). We observed three distinct
phases: Phase I of slow deposition of platelets on the collagen surface lasting for
several minutes; Phase II with large thrombus thickening where platelets accumulated
rapidly at rates exceeding 1.6 µm3 µm−2 min−1, and a Phase III of total occlusion
with cessation of blood flow.[2] The length of time in Phase I was called the ”lag
time” and represents the attachment of only a few thousand platelets. In contrast,
Phase II represents the accumulation of hundreds of millions of platelets and is likely
a different mechanism than Phase I attachment. It is difficult to distinguish between
a single mechanism for both phases or two total mechanisms based on the sampling
allowed for manual image processing. These experiments quantified the thrombus
thickness and accumulation rates with much greater resolution than previous studies.
However, our general findings are in good agreement with low-resolution observations
made by previous investigators.
The first experiments used 240 ml of blood. A second system was devised to reduce
the required blood volume to 30 ml. This second system was verified to yield similar
thrombosis with porcine blood, then utilized to study human blood (Chapter 3).
The human blood showed a similar Phase I and II, but with quantitative differences.
Human blood shows a lag time that is over 7 minutes and an RPA rate that is 4.5 µm3
µm−2 min−1, half as fast as RPA in porcine blood. RPA occurred in approximately
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22.4% (28/125) of experiments. These results are consistent with the perception that
pigs are hypercoagulable compared to humans.
The system was then used to compare anti-platelet efficacy at reducing high shear
thrombosis as measured by thrombus thickness and accumulation rate (Chapter 4).
Our in vitro assay demonstrates features seen clinically, i.e. high shear platelet throm-
bosis is inhibited by activation and αIIbβ3 blockers. The test further demonstrates
that different anti-platelet agents have different efficacy, consistent with clinical expe-
rience. Further, our findings provide an alternative view from Ruggeri’s findings that
high shear platelet aggregation does not require activation or αIIbβ3.[1] Instead, we
find that large accumulation of thrombus under high shear is prevented by activation
blockade or specific αIIbβ3 blockade. Both results may be resolved by defining a mech-
anism by which high shear circulating platelet attachment/adhesion occurs via GPIb
without activation but high shear thrombus accumulation over several minutes re-
quires stabilization from αIIbβ3 conformation change. An additional distinction may
be that our high resolution thickness measurements allow the separation of Phase
II accumulation from the Phase I attachment/aggregation that is more likely in the
Ruggeri experiments. The results are clinically significant as we find in vitro quan-
tification of thrombosis similar to previous literature describing patient response to
the anti-platelets.
Lastly, we use our system to investigate whether excess (soluble or immobilized)
vWF can increase either thrombus thickness or accumulation rate (Chap 5). In our
system, the thrombus thickness increased by 100% with excess plasma (soluble) vWF
for very high shear (10,000s−1) but not at 3,500s−1. In contrast, (immobilized) vWF
deposited on the surface (under static conditions) did not have a significant effect at
either high hemodynamic shear rates. As vWF may have more of an impact on Phase
I, future experimentation may include the study of vWF immobilized to the stenosis
surface prior to perfusion to measure the influence of vWF enrichment on Phase I.
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The results of this dissertation indicate that thrombus formation within arterial
stenosis is dominated by a Phase II rapid platelet accumulation. This formation
is best characterized by an assay that can measure the thickness accumulation of
millions of platelets rather than a surface attachment of a few platelets. Since clinical
thrombosis arises from shear induced platelet accumulation (SIPA), patient-specific
testing of whole blood at high shears may provide better titration of anti-platelet
agents than static ristocetin or simple membrane occlusion assays. While high doses
of some anti-platelet medications may prevent all thrombogenic effects in the blood,
they may also create detrimental bleeding side effects for patients. Using a patient-
specific assay would enable physicians to titrate anti-platelet medications to levels
which prevent thrombosis only at very high shears without preventing all platelet
deposition, thus preserving normal haemostasis.
Currently patients are being administered therapies based on recommendations
via population studies and do not tailor their therapy regimes due to the patients
themselves. Our findings in this thesis show that patients may benefit from patient-
specific testing as one patient may not respond to all αIIbβ3 inhibitors or activation
inhibitors equally. In the future, our system may be modified as a point-of-care
system to provide accurate patient-specific titrations. Further, we find that patients
may show a time dependent response, which may require adjustment of therapeutic
doses within the time-span of a month similar to coumadin.
The hemodynamic system may be used for patient-specific testing of whole blood
at high shear rates. The device would need to be modified so that the manual method
of setup and measurement is automated. If the blood delivered upstream would be
in a vacutainer, the device would be convenient with current phlebotomy practices.
Multiple stenoses may also be placed upstream to simulate multiple plaques in a
single artery and potentially preactivate platelets. An ideal model would also have a
high throughput so that many therapies could be tested at once, decreasing the time
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from blood draw to therapy formulation.
This BioEngineering thesis describes a method for quantifying the potential of
human blood for high shear occlusive thrombosis, distinguishes a phenomenon of
Rapid Platelet Accumulation, and demonstrates the utility of such a system to explore
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Figure 43: A detailed image of the syringe pump components are shown above. Flow
is from left to right. Blood flows from the syringe pump, past the pressure transducer
and into the stenotic test section. During experimentation there is usually a tube
connected to the downstream end of the stenosis so that the blood cleanly flows
into a waste container (not shown). The 3-way valve used posessed a 1.6mm inner
diameter ensuring that the highest shear was located in the throat of the stenosis.
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Figure 44: Scatter plot of time versus volume of blood required for visible initial
formation in the human syringe pump model, the porcine syringe pump model and
the porcine gravitationally fed model.
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Figure 45: The average time to visible initial formation is shown above for the human
syringe pump model, the porcine syringe pump model and the porcine gravitationally
fed model. The bars denote the standard deviation. The time to initial formation
for the human syringe pump model is significantly higer (7.4 ± 3.8 min) than the
porcine syringe pump model (2.7 ± 4.9 min, α, p<0.05) and the porcine gravitation-
ally fed model (1.0 ± 0.9min, β, p<0.05). The porcine gravitationally fed model is
significantly faster (γ, p<0.05) then the porcine syringe pump model.
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